

## Prof. YUSUF YILMAZ

### Personal Information

**Fax Phone:** [+90 533 440 3995](tel:+905334403995)

**Email:** [yusuf.yilmaz@marmara.edu.tr](mailto:yusuf.yilmaz@marmara.edu.tr)

**Other Email:** [dryusufyilmaz@gmail.com](mailto:dryusufyilmaz@gmail.com)

**Web:** <https://avesis.marmara.edu.tr/yusuf.yilmaz>

### International Researcher IDs

ScholarID: -xUdXf8AAAAJ

ORCID: 0000-0003-4518-5283

Publons / Web Of Science ResearcherID: K-6651-2012

ScopusID: 22936014300

Yoksis Researcher ID: 187733

### Biography

1978 yılında Rize'de doğan Yusuf Yılmaz 1996 yılında İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi'ni kazanarak dereceyle mezun olma başarısını göstererek 2002 yılında 'Tıp Doktoru' ünvanını almıştır. Aynı yıl tıpta uzmanlık sınavını kazanarak Uludağ Üniversitesi Tıp Fakültesi'ne girmiştir, 2007 yılında 'İç Hastalıkları Uzmanı' olmuştur. Kısa bir süre zorunlu hizmet görevini yerine getirerek 2008 yılında kazandığı yan dal sınavı ile Marmara Üniversitesi Tıp Fakültesi Gastroenteroloji Bilim Dalı'nda yan dal uzmanlık eğitimiine başlamıştır. 2011 yılında 'Gastroenteroloji Uzmanı' da olan ve aynı yıl Doçentlik sınavını da başarıyla veren Yusuf Yılmaz 2012 yılında Marmara Üniversitesi Tıp Fakültesi'ne 'Öğretim Üyesi' olarak atanmıştır. 2017 yılında tıp fakültesine atanın en genç 'Profesör' olmuştur. 2018 yılında dünyada 'Tıp Bilimine Yön Veren 100 Türk' arasına girmiştir.

Prof. Dr. Yusuf Yılmaz'ın uluslararası yabancı dergilerde yayımlanmış 150'ye yakın bilimsel araştırması bulunmaktadır. Uluslararası bir kuruluş olan Webometrics 2016 verilerine göre Dr. Yusuf Yılmaz, Türkiye'deki tüm bilim insanları içerisinde (sadece tıp alanında değil) 223. sıraya yerleşme başarısına bu genç yaşında ulaşmıştır. Google Akademik 2018 verilerine göre >30 h endeksi ve 4000 alıntılanma sayısı ile ülkemizin en iyi akademisyenleri arasında gösterilmektedir.

Yüksek özverili çalışmaları sayesinde alanında sadece dünyaca ünlü bilim insanların davet edilerek derlemelerinin yayımlandığı prestijli dergilerde yazar olma başarısını göstermiştir. Bütün bu başarılar sayesinde uluslararası NASH komitesine seçilen Avrupa'dan sayılı birkaç bilim insanından biridir. Ayrıca Avrupa Karaciğer Araştırmaları Derneği, Amerikan Karaciğer Araştırmaları Derneği, Amerikan Kronik Karaciğer Vakfı üyeliği bulunmaktadır.

Hepatology, Journal of Hepatology, Alimentary Pharmacology and Therapeutics, Diabetes Care , Metabolism gibi 50'den fazla uluslararası dergide hakemlik görevi bulunmaktadır. Çeşitli yıllarda en iyi hakem, en fazla alıntı yapılan araştırma, en çok alıntı yapılan derleme sahibi bilim insanı başarısını da göstermiştir.

Türkiye'de Fibroscan kullanımında en deneyimli kişi olan Prof. Dr. Yusuf Yılmaz, bu deneyimini gerek yurt içinde gerekse yurt dışında hekimlere yönelik eğitim kurslarıyla meslektaşlarıyla paylaşmaktadır.

### Education Information

Post Doctorate of Medicine, Marmara University, School of Medicine, Turkey 2008 - 2011

Expertise In Medicine, Uludağ Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2002 - 2007

Undergraduate, İstanbul University, Cerrahpaşa Tıp Fakültesi, Turkey 1996 - 2002

## **Foreign Languages**

English, C1 Advanced

## **Research Areas**

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Gastroenterology and Hepatology

## **Academic Titles / Tasks**

Professor, Marmara University, School of Medicine, Internal Medical Sciences, 2017 - Continues

## **Academic and Administrative Experience**

Marmara University, Institute of Gastroenterology, 2014 - Continues

## **Advising Theses**

Yılmaz Y., OBEZ HASTALarda KARACİĞER YAĞLANMASININ VE FİBROZİSİNİN FİBROSCAN İLENONİVAZİV OLARAK DEĞERLENDİRİLMESİ, Expertise In Medicine, A.AVCU(Student), 2020

Yılmaz Y., Fibroscan'in nonalkolik yağlı karaciğer hastalığındaki tanısal performansının değerlendirilmesi, Expertise In Medicine, F.JAFAROV(Student), 2019

Yılmaz Y., Biyopsi kanıtlı non-alkolik yağlı karaciğer hastalığı bulunan bireylerde tip 2 diabetes mellitus, metabolik sendrom ve obezite prevalansının değerlendirilmesi, Expertise In Medicine, H.JAFAROVA(Student), 2019

Güneş F. E., Yılmaz Y., Alkolik olmayan karaciğer yağlanması olan hastalarda bağırsaktaki faecalibacterium prausnitzii ve eubacterium rectale bakterilerinin değişimlerinin uygulanan diyet modeli ile ilişkilendirilmesi, Postgraduate, E.OĞUZ(Student), 2019

Yılmaz Y., Nonalkolik karaciğer yağlanması bulunan hastalarda aterosklerozun ve karaciğer sertliğinin noninvazifdeğerlendirilmesi, Expertise In Medicine, B.Ören(Student), 2019

Yılmaz Y., Fibroscan'in nonalkolik yağlı karaciğer hastalığındaki tanısal performansının değerlendirilmesi, Expertise In Medicine, F.Jafarov(Student), 2019

Tüfekçi Alphan M. E., Yılmaz Y., Normal kilolu non-alkolik yağlı karaciğer hastalığı olan bireylerde tıbbi beslenme tedavisinin etkinliğinin değerlendirilmesi, Doctorate, P.HAMURCU(Student), 2018

Yılmaz Y., Tip 2 diyabetli hastalarda karaciğer sertliğinin ve yağlanması Fibroscan ile saptanması, Expertise In Medicine, M.Demir(Student), 2018

Yılmaz Y., Non-alkolik yağlı karaciğerli hastalarda ileri evre fibrozisin saptanmasında non-invaziv fibrozis testlerinin tanısal performansı, Expertise In Medicine, C.FIRAT(Student), 2015

Yılmaz Y., Nonalkolik yağlı karaciğerli hastalarda ileri evre fibrozisin saptanmasında noninvaziv yeni bir yöntem olan fibrometer VCTE'nin tanısal performansı, Expertise In Medicine, E.DİNÇSES(Student), 2015

YILMAZ Y., Nonalkolik yağlı karaciğerli hastalarda ileri evre fibrozisin saptanmasında noninvaziv yeni bir yöntem olan fibrometerm vcte'nin tanısal performansı, Expertise In Medicine, E.Dinçses(Student), 2015

Yılmaz Y., Nonalkolik yağlı karaciğer hastalığında fibrozisin noninvaziv yöntemlerle araştırılması, Expertise In Medicine, U.EMRE(Student), 2014

## **Jury Memberships**

Associate Professor Exam, Associate Professor Exam, Üniversitelerarası Kurul, August, 2020

## **Published journal articles indexed by SCI, SSCI, and AHCI**

- I. **Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study**  
Anstee Q. M., Lucas K. J., Francque S., Abdelmalek M. F., Sanyal A. J., Ratziu V., Gadano A. C., Rinella M., Charlton M., Loomba R., et al.  
*Hepatology*, vol.78, no.4, pp.1223-1239, 2023 (SCI-Expanded)
- II. **An international multidisciplinary consensus statement on MAFLD and the risk of CVD**  
Zhou X., Targher G., Byrne C. D., Somers V., Kim S. U., Chahal C. A. A., Wong V. W., Cai J., Shapiro M. D., Eslam M., et al.  
*Hepatology International*, vol.17, no.4, pp.773-791, 2023 (SCI-Expanded)
- III. **An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease**  
Sun D., Targher G., Byrne C. D., Wheeler D. C., Wong V. W., Fan J., Tilg H., Yuan W., Wanner C., Gao X., et al.  
*HEPATOBILIARY SURGERY AND NUTRITION*, vol.12, no.3, 2023 (SCI-Expanded)
- IV. **Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice**  
Lazarus J. V., Castera L., Mark H. E., Allen A. M., Adams L. A., Anstee Q. M., Arrese M., Alqahtani S. A., Bugianesi E., Colombo M., et al.  
*JHEP Reports*, vol.5, no.1, 2023 (SCI-Expanded)
- V. **Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study**  
YILMAZ Y., Toraman A. E., Alp C., Dogan Z., Keklikiran C., Stepanova M., Younossi Z.  
*ALIMENTARY PHARMACOLOGY & THERAPEUTICS*, vol.57, no.2, pp.215-223, 2023 (SCI-Expanded)
- VI. **The effects of dietary intervention on fibrosis and biochemical parameters in metabolic-associated fatty liver disease.**  
Ozlu T., Yilmaz Y., Gunes F. E.  
*Minerva gastroenterology*, vol.68, pp.426-433, 2022 (SCI-Expanded)
- VII. **Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry**  
Younossi Z. M., Yu M., El-Kassas M., Esmat G., Fernandez M. I. C., Buti M., Papatheodoridis G., YILMAZ Y., Isakov V., Duseja A., et al.  
*JOURNAL OF VIRAL HEPATITIS*, vol.29, no.11, pp.1015-1025, 2022 (SCI-Expanded)
- VIII. **CLINICAL AND PATIENT-REPORTED OUTCOME (PRO) PROFILE OF PATIENTS WITH HEPATITIS B VIRAL (HBV) INFECTION FROM THE GLOBAL LIVER REGISTRY (TM) (GLR (TM))**  
Younossi Z. M., YILMAZ Y., Yu M., Alswat K. A., Buti M., Fernandez M. I. C., Papatheodoridis G., Hamid S. S., El Kassas M., Chan W. K., et al.  
*HEPATOLOGY*, vol.76, 2022 (SCI-Expanded)
- IX. **Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry.**  
Younossi Z. M., Yilmaz Y., Yu M., Wai-Sun Wong V., Fernandez M. C., Isakov V. A., Duseja A. K., Mendez-Sanchez N., Eguchi Y., Bugianesi E., et al.  
*Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, vol.20, no.10, pp.2296, 2022 (SCI-Expanded)
- X. **DEPRESSION AND EMOTIONAL DISTRESS IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (TM) (GLR (TM))**  
Younossi Z. M., Stepanova M., Fernandez M. I. C., YILMAZ Y., Yu M., El Kassas M., Esmat G., Isakov V. A., Wong V. W., Eguchi Y., et al.  
*HEPATOLOGY*, vol.76, 2022 (SCI-Expanded)
- XI. **REAL-WORLD EVIDENCE ON NON-INVASIVE TESTS AND ASSOCIATED CUT-OFFS USED TO ASSESS FIBROSIS IN ROUTINE CLINICAL PRACTICE**  
Lazarus J. V., Castera L., Mark H., Adams L. A., Allen A. M., Anstee Q. M., Arrese M., Alqahtani S., Bugianesi E.,

- Colombo M., et al.  
HEPATOLOGY, vol.76, 2022 (SCI-Expanded)
- XII. **The impact of the COVID-19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry**  
Younossi Z. M., Yilmaz Y., El-Kassas M., Duseja A., Hamid S., Esmat G., Mendez-Sanchez N., Chan W. K., Singal A. K., Lam B., et al.  
HEPATOLOGY COMMUNICATIONS, vol.6, no.10, pp.2860-2866, 2022 (SCI-Expanded)
- XIII. **Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease**  
Younossi Z., Yilmaz Y., El Kassas M., Duseja A. K., Hamid S. S., Esmat G., Mendez-Sanchez N., Chan W., Singal A., Ong J., et al.  
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- XIV. **Lean non-alcoholic fatty liver disease patients from the global NASH registry**  
Younossi Z., Yilmaz Y., Yu M., Wong V. W., Castellanos-Fernandez M., Isakov V., Duseja A. K., Mendez-Sanchez N., Eguchi Y., Bugianesi E., et al.  
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- XV. **Multimodality assessment of hepatic fibrosis: ranked paired reading and artificial intelligence identifies fibrosis improvement with aramchol missed by conventional staging**  
Ratziu V., Yilmaz Y., Lazas D., Friedman S., Lackner C., Behling C., Cummings O., Chen L., Petitjean M., Gilgun-Sherki Y., et al.  
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- XVI. **Higher daily Aramchol dose results in higher effect size in fibrosis improvement in the ARMOR study open label part**  
Ratziu V., Yilmaz Y., Lazas D., Friedman S., Hayardeny L., Kadosh S., Gorfine T., Sanyal A.  
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- XVII. **A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease.**  
Younossi Z. M., Ong J. P., Takahashi H., Yilmaz Y., Eguchi Y., El Kassas M., Buti M., Diago M., Zheng M., Fan J., et al.  
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol.20, 2022 (SCI-Expanded)
- XVIII. **Global multi-stakeholder endorsement of the MAFLD definition.**  
Méndez-Sánchez N., Bugianesi E., Gish R. G., Lammert F., Tilg H., Nguyen M. H., Sarin S. K., Fabrellas N., Zelber-Sagi S., Fan J., et al.  
The lancet. Gastroenterology & hepatology, vol.7, no.5, pp.388-390, 2022 (SCI-Expanded)
- XIX. **Fibroscan detection of fatty liver and liver fibrosis in patients with systemic lupus erythematosus.**  
Yetginoglu O., Atas D., Yilmaz Y., Velioglu A., Arikan H., Alibaz-Oner F., Direskeneli H., Tuglular S., Asicioglu E.  
Lupus, vol.31, no.6, pp.723-729, 2022 (SCI-Expanded)
- XX. **Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.**  
Mózes F. E., Lee J. A., Selvaraj E. A., Jayaswal A. N. A., Trauner M., Boursier J., Fournier C., Staufer K., Stauber R. E., Bugianesi E., et al.  
Gut, vol.71, pp.1006-1019, 2022 (SCI-Expanded)
- XXI. **The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?**  
Lazarus J. V., Mark H. E., Villota-Rivas M., Palayew A., Carrieri P., Colombo M., Ekstedt M., Esmat G., George J., Marchesini G., et al.  
Journal of hepatology, vol.76, pp.771-780, 2022 (SCI-Expanded)
- XXII. **Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver**  
Kaya E., Yilmaz Y.  
Journal of Clinical and Translational Hepatology, vol.10, no.2, pp.329-338, 2022 (SCI-Expanded)
- XXIII. **Advancing the global public health agenda for NAFLD: a consensus statement**  
Lazarus J., Mark H. E., Anstee Q. M., Arab J. P., Batterham R. L., Castera L., Cortez-Pinto H., Crespo J., Cusi K., Dirac M.

- A., et al.  
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, vol.19, pp.60-78, 2022 (SCI-Expanded)
- XXIV. **Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals.**  
Eren F., Kaya E., Yilmaz Y.  
European journal of gastroenterology & hepatology, vol.34, pp.98-103, 2022 (SCI-Expanded)
- XXV. **Macro- and micronutrients in metabolic (dysfunction) associated fatty liver disease: association between advanced fibrosis and high dietary intake of cholesterol/saturated fatty acids.**  
Guveli H., Kenger E. B., Ozlu T., Kaya E., Yilmaz Y.  
European journal of gastroenterology & hepatology, vol.33, 2021 (SCI-Expanded)
- XXVI. **COVID-19 PANDEMIC AND CHRONIC LIVER DISEASE (CLD)**  
Younossi Z. M., YILMAZ Y., El Kassas M., Duseja A. K., Hamid S. S., Esmat G., Mendez-Sanchez N., Chan W. K., Singal A. K., Lam B. P., et al.  
HEPATOLOGY, vol.74, 2021 (SCI-Expanded)
- XXVII. **A NOVEL STUDY DESIGN WITH ARAMCHOL EXPLORING THE KINETICS AND INTER-RELATIONS OF HISTOLOGICAL OUTCOME MEASURES AND NON-INVASIVE TESTS ASSOCIATED WITH NASH AND FIBROSIS FOR VARIABLE TREATMENT DURATIONS**  
Ratziu V., YILMAZ Y., Lazas D., De Guevara L. L., Kadosh S., Gorfine T., Sanyal A. J.  
HEPATOLOGY, vol.74, 2021 (SCI-Expanded)
- XXVIII. **acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study.**  
Wu X., Zheng K. I., Boursier J., Chan W., Yilmaz Y., Romero-Gómez M., El Kassas M., Targher G., Byrne C. D., Huang Z., et al.  
EClinicalMedicine, vol.41, pp.101145, 2021 (SCI-Expanded)
- XXIX. **FATIGUE AND NON-ALCOHOLIC FATTY LIVER DISEASE: DATA FROM THE GLOBAL NASH REGISTRY**  
Younossi Z. M., YILMAZ Y., Wong V. W., Fernandez M. I. C., Bugianesi E., Burra P., Yu M., Chan W. K., Isakov V. A., Duseja A. K., et al.  
HEPATOLOGY, vol.74, 2021 (SCI-Expanded)
- XXX. **Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study**  
Demirtas C. O., Keklikkiran C., Ergenc I., Erturk Sengel B., Eskidemir G., Cinel I., Odabasi Z., Korten V., Yilmaz Y.  
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.75, no.9, 2021 (SCI-Expanded)
- XXXI. **Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease**  
KANİ H. T., DEMİRTAŞ C. Ö., KEKLİKKIRAN Ç., Ergenc I., Mehdiyev S., AKDENİZ E., YILMAZ Y.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.8, pp.661-666, 2021 (SCI-Expanded)
- XXXII. **Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease**  
Younossi Z., Harrison S., Newsome P. N., Chan W., YILMAZ Y., de Ledinghen V., Costentin C., Zheng M., Wong V. W., Elkhashab M., et al.  
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- XXXIII. **Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement.**  
Hagström H., Adams L. A., Allen A. M., Byrne C. D., Chang Y., Grønbaek H., Ismail M., Jepsen P., Kanwal F., Kramer J., et al.  
Hepatology (Baltimore, Md.), vol.74, pp.474-482, 2021 (SCI-Expanded)
- XXXIV. **The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry**  
Younossi Z., YILMAZ Y., El-Kassas M., Duseja A. K., Hamid S. S., Esmat G., Mendez-Sanchez N., Chan W., Singal A., Lam B., et al.

- JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- XXXV. Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosis  
Mozes F., Lee J., Selvaraj E., Jayaswal A., Trauner M., Boursier J., Fournier C., Staufer K., Stauber R., Bugianesi E., et al.  
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- XXXVI. Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease-simply associated or more complicated?  
Demirtas C. O., Yilmaz Y.  
Alimentary pharmacology & therapeutics, vol.53, pp.1228-1229, 2021 (SCI-Expanded)
- XXXVII. FIBROSCAN DETECTION OF FATTY LIVER AND LIVER FIBROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS  
YETGİNOĞLU Ö., Atas D. B., VELİOĞLU A., ARIKAN İ. H., YILMAZ Y., ALİBAZ ÖNER F., DİRESKENELİ R. H., TUĞLULAR Z. S., AŞİCİOĞLU E.  
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.36, pp.172, 2021 (SCI-Expanded)
- XXXVIII. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic  
AVCU A., Kaya E., YILMAZ Y.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.5, pp.466-472, 2021 (SCI-Expanded)
- XXXIX. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD.  
Yilmaz Y., Byrne C., Musso G.  
Expert review of gastroenterology & hepatology, vol.15, pp.345-352, 2021 (SCI-Expanded)
- XL. Recommendations for Reopening Endoscopy Units in Turkey: A Set-up Plan from a Tertiary Center in Istanbul.  
Demirtas C. Ö., Keklikkiran Ç., Mehdiyev S., Ergenç İ., Özgen Alahdab Y., Gündüz F., Yilmaz Y., Atuğ Ö., Özdogan O. C.  
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.32, pp.113-115, 2021 (SCI-Expanded)
- XLI. The case for simplifying and using absolute targets for viral hepatitis elimination goals.  
Razavi H., Blach S., Razavi-Shearer D., Polaris O.  
Journal of viral hepatitis, vol.28, pp.12-19, 2021 (SCI-Expanded)
- XLII. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease  
Eslam M., Sarin S., Wong V., Fan J., Kawaguchi T., Ahn S., Zheng M., Shiha G., Yilmaz Y., Gani R., et al.  
HEPATOLOGY INTERNATIONAL, vol.14, no.6, pp.889-919, 2020 (SCI-Expanded)
- XLIII. Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam's razor applied to advanced fibrosis screening.  
Yilmaz Y., Kaya E., Eren F.  
Alimentary pharmacology & therapeutics, vol.52, pp.1759-1760, 2020 (SCI-Expanded)
- XLIV. Impact of aerobic training with and without whole-body vibration training on metabolic features and quality of life in non-alcoholic fatty liver disease patients.  
Saldırın T., Mutluay F., Yağcı İ., Yilmaz Y.  
Annales d'endocrinologie, vol.81, pp.493-499, 2020 (SCI-Expanded)
- XLV. Effect of carbon dioxide versus room air insufflation on post-colonoscopic pain: A prospective, randomized, controlled study.  
Gündüz F., Kani H. T., Chang S., Akdeniz E., Eren F., Yilmaz Y., Alahdab Y.  
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.31, no.10, pp.676-680, 2020 (SCI-Expanded)
- XLVI. Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients.  
Hamurcu V., Kaya E., Alphan E., Yilmaz Y.

- European journal of gastroenterology & hepatology, vol.32, pp.1352-1357, 2020 (SCI-Expanded)
- XLVII. Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD.**
- Sun D., Ye F., Kani H. T., Yang J., Zheng K., Zhang H., Targher G., Byrne C., Chen Y., Yuan W., et al. Diabetes & metabolism, vol.46, no.4, pp.288-295, 2020 (SCI-Expanded)
- XLVIII. Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease.**
- Kaya E., Bakir A., Kani H. T., Demirtas C., Keklikiran C., Yilmaz Y. Gut and liver, vol.14, no.4, pp.486-491, 2020 (SCI-Expanded)
- XLIX. A new definition for metabolic associated fatty liver disease: an international expert consensus statement.**
- Eslam M., Newsome P., Anstee Q., Targher G., Gomez M., Zelber-Sagi S., Wong V., Dufour J., Schattenberg J., Arrese M., et al. Journal of hepatology, vol.73, pp.202-209, 2020 (SCI-Expanded)
- L. External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients.**
- Demirtas C., Gunduz F., Kani H. T., Keklikiran C., Alahdab Y., Yilmaz Y., Duman D., Atug O., Giral A., Aslan R., et al. European journal of gastroenterology & hepatology, vol.32, no.7, pp.882-888, 2020 (SCI-Expanded)
- LI. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.**
- Alkayyali T., Qutranji L., Kaya E., Bakir A., Yilmaz Y. Acta diabetologica, vol.57, no.5, pp.613-618, 2020 (SCI-Expanded)
- LII. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.**
- Eslam M., Sanyal A., George J., International C. Gastroenterology, vol.158, 2020 (SCI-Expanded)
- LIII. The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study**
- Jafarov F., Kaya E., Bakir A., Eren F., Yilmaz Y. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.32, pp.642-649, 2020 (SCI-Expanded)
- LIV. The interaction between current smoking and hemoglobin on the risk of advanced fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease.**
- Enc F., Ulasoglu C., Bakir A., Yilmaz Y. European journal of gastroenterology & hepatology, vol.32, pp.597-600, 2020 (SCI-Expanded)
- LV. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.**
- Newsome P., Sasso M., Deeks J., Paredes A., Boursier J., Chan W., Yilmaz Y., Czernichow S., Zheng M., Wong V., et al. The lancet. Gastroenterology & hepatology, vol.5, pp.362-373, 2020 (SCI-Expanded)
- LVI. Letter: a stepwise approach towards the screening of hepatic fibrosis in the general population.**
- Yilmaz Y. Alimentary pharmacology & therapeutics, vol.51, pp.669-670, 2020 (SCI-Expanded)
- LVII. Letter: the perilous road to a functional cure for hepatitis B infection.**
- Yilmaz Y. Alimentary pharmacology & therapeutics, vol.51, pp.577, 2020 (SCI-Expanded)
- LVIII. NFS Is Not a Marker of Nonalcoholic Fatty Liver Disease Per Se: What Is the True Relationship With CAD Complexity?**
- Yilmaz Y., Eren F. ANGIOLOGY, vol.71, pp.83-84, 2020 (SCI-Expanded)
- LIX. Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study.**
- Bilgin B., Sunbul M., Kani H. T., Demirtas C., Keklikiran C., Yilmaz Y.

- European journal of gastroenterology & hepatology, vol.32, pp.54-57, 2020 (SCI-Expanded)
- LX. **Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels.**  
Ulasoglu C., Enc F., Kaya E., Yilmaz Y.  
Journal of gastrointestinal and liver diseases : JGLD, vol.28, pp.427-431, 2019 (SCI-Expanded)
- LXI. **Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter**  
Yilmaz Y., Eren F.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.31, no.12, pp.1601-1602, 2019 (SCI-Expanded)
- LXII. **Comments on "The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease"**  
Yilmaz Y., Eren F.  
SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES, vol.29, no.6, pp.548, 2019 (SCI-Expanded)
- LXIII. **Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.**  
Tatar B., Köse Ş., Ergun N., Turken M., Onlen Y., Yilmaz Y., Akhan S.  
Revista da Associacao Medica Brasileira (1992), vol.65, pp.1470-1475, 2019 (SCI-Expanded)
- LXIV. **Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis**  
Hasturk B., Yilmaz Y., Eren F.  
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, vol.18, pp.463-475, 2019 (SCI-Expanded)
- LXV. **Hepatic fibrosis - and not steatosis - is the main determinant of arterial stiffness in non-alcoholic fatty liver disease**  
Yilmaz Y., Eren F.  
ATHEROSCLEROSIS, vol.290, pp.222-223, 2019 (SCI-Expanded)
- LXVI. **Non-alcoholic fatty liver disease: A growing public health problem in Turkey**  
Kaya E., YILMAZ Y.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.10, pp.865-871, 2019 (SCI-Expanded)
- LXVII. **Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents**  
Kesen O., Kani H. T., Yanartaş Ö., Aykut U., Gök B., Gündüz F., Yılmaz Y., Özdoğan O. C., Özgen A.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.9, pp.801-806, 2019 (SCI-Expanded)
- LXVIII. **Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease**  
Younossi Z. M., Stepanova M., Ong J., Yilmaz Y., Duseja A., Eguchi Y., El Kassas M., Castellanos-Fernandez M., George J., Jacobson I. M., et al.  
Clinical Gastroenterology and Hepatology, vol.17, pp.1625, 2019 (SCI-Expanded)
- LXIX. **Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis**  
Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E., Wai-Sun Wong V., Yilmaz Y., George J., Fan J., et al.  
Hepatology, vol.69, pp.2672-2682, 2019 (SCI-Expanded)
- LXX. **Liver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease**  
Dq S., Fang Zhoе Y., KANİ H. T., Chen Fei Z., Pei Wu Z., Hong Lei M., Wen Yue L., Hao Yang Z., Xiao Dong W., Wei Jie Y., et al.  
Journal Of Hepatology, vol.70, pp.787, 2019 (SCI-Expanded)
- LXXI. **Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates**  
Younossi Z., Stepanova M., Ong J. P., Jacobson I. M., Bugianesi E., Duseja A., Eguchi Y., Wong V. W., Negro F., Yilmaz H. Y., et al.

- CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.17, no.4, pp.748-758, 2019 (SCI-Expanded)
- LXXII. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study  
DEMİR M., Deyneli O., YILMAZ Y.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.3, pp.266-270, 2019 (SCI-Expanded)
- LXXIII. The optimal controlled attenuation parameter cut-offs in hepaticsteatosis grade differentiation by transient elastography(Fibroscan) in a sample of biopsy-proven non-alcoholic fatty liverdisease patients  
Kaya E., BAKIR A., Sapmaz A. F., Kayyali T., Quatranji L., Çiftaslan A., Demirtas C. O., DEMİRTAŞ C. Ö., KANI H. T., YILMAZ Y.  
Hepatology International, vol.13, pp.196, 2019 (SCI-Expanded)
- LXXIV. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology  
YILMAZ Y., EREN F.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.31, no.1, pp.43-46, 2019 (SCI-Expanded)
- LXXV. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.  
Yilmaz Y., Kani H. T., Demirtas C., Kaya E., Sapmaz A., Qutranji L., Alkayyali T., Batun K., Batman M., Toy B., et al.  
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.30, pp.892-898, 2019 (SCI-Expanded)
- LXXVI. THE SEQUENCE ANALYSIS OF NEW MITOCHONDRIALGENE, MOTS-C, IN PATIENTS WITH THE NON-ALCOHOLICSTEATOHEPATITIS  
Önal O., Eren F., Yilmaz D., Göçmen T., Yilmaz Y.  
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, vol.6, pp.135, 2018 (SCI-Expanded)
- LXXVII. Nonalcoholic Fatty Liver Disease(NAFLD) and Alcoholic Fatty Liver Disease(AFLD): The impact of Alcohol Comsumption and Metabolic Syndrome on Mortality  
Younossi Z., Maria S., Ong J., Yilmaz Y., Duseja A., Eguchi Y., Elkassas M., Castel L., Fernandez V., George J., et al.  
Hepatology, vol.68, pp.1, 2018 (SCI-Expanded)
- LXXVIII. Development of multiplex single base primer extension assay for the detection of potential association between MTNR1B gene polymorphisms and NASH  
Yilmaz D., Eren F., Göçmen T., Yilmaz Y.  
Journal Of Biotechnology, vol.280, pp.76, 2018 (SCI-Expanded)
- LXXIX. The correlation between histopathologic steatosis/fibrosis and various non-invasive imagingand blood fibrosis indicators of overweight and obese children  
Tutar E., Şahin Akkelle B., Kesici C. B., Yilmaz Y., Çelikel Ç., Ergelen R., Ertem Şahinoğlu D.  
Journal Of Pediatric Gastroenterology And Nutrition, vol.66, 2018 (SCI-Expanded)
- LXXX. The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease  
Ozturk K., Dogan T., Celikkanat S., Ozen A., Demirci H., Kurt O., Turker T., YILMAZ Y., Uygun A.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.30, no.4, pp.411-417, 2018 (SCI-Expanded)
- LXXXI. Transient elastography with controlled attenuation parameter in the assessment of hepatic steatosis and significant liver fibrosis in patients with scleroderma  
Yilmaz Y., Kani H. T., Şahinkaya Y., Deliktaş İ., Mursaloğlu H. H., Aziziy M., İnanç G. N., Direskeneli R. H.  
Hepatology International, vol.12, 2018 (SCI-Expanded)
- LXXXII. Recommendation for treatment of hepatitis C virus infection  
KAYMAKOĞLU S., Koksal I., KAYMAKOĞLU S., Tabak F., Akarca U. S., Akbulut A., AKYÜZ F., Bodur H., ÇAĞATAY A. A., Dincer D., et al.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, 2017 (SCI-Expanded)
- LXXXIII. Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases  
YILMAZ Y., EREN F.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, no.5, pp.327-328, 2017 (SCI-Expanded)
- LXXXIV. The association of nonalcoholic fatty liver disease with genetic polymorphisms: A multicenter study

- Uygun A., Ozturk K., Demirci H., Oztuna A., Eren F., Kozan S., Yilmaz Y., Kurt O., Turker T., Vatansever S., et al. European Journal of Gastroenterology and Hepatology, vol.29, pp.441-447, 2017 (SCI-Expanded)
- LXXXV. **Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter**  
Kaya E., Demir D., ÖZEN ALAHDAB Y., YILMAZ Y.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.28, no.11, pp.1264-1267, 2016 (SCI-Expanded)
- LXXXVI. **Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis**  
ERGELEN R., YILMAZ Y., Asedov R., ÇELİKEL Ç., Akin H., BUĞDAYCI O., Altun E., TÜNEY D.  
ABDOMINAL RADIOLOGY, vol.41, no.8, pp.1505-1510, 2016 (SCI-Expanded)
- LXXXVII. **The role of active brown adipose tissue in human metabolism**  
Ozguven S., Ones T., Yilmaz Y., Turoglu H. T., Imeryuz N.  
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.43, no.2, pp.355-361, 2016 (SCI-Expanded)
- LXXXVIII. **Is NAFLD different in absence of metabolic syndrome?**  
YILMAZ Y.  
CLINICAL DILEMMAS IN NON-ALCOHOLIC FATTY LIVER DISEASE, pp.44-49, 2016 (SCI-Expanded)
- LXXXIX. **Diagnostic Role of Colon Capsule Endoscopy in Patients with Optimal Colon Cleaning**  
Akyüz Ü., Yilmaz Y., Ince A. T., Kaya B., Pata C.  
Gastroenterology Research and Practice, vol.2016, 2016 (SCI-Expanded)
- XC. **Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease**  
Dincses E., YILMAZ Y.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.27, no.10, pp.1149-1153, 2015 (SCI-Expanded)
- XCI. **Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease**  
Sünbül M., Kivrak T., Durmus E., Akin H., Aydin Y., Ergelen R., Yilmaz Y., Agirbasli M.  
CARDIOVASCULAR THERAPEUTICS, vol.33, pp.294-299, 2015 (SCI-Expanded)
- XCII. **Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease**  
Ozturk O., ÇOLAK Y., ŞENATEŞ E., YILMAZ Y., Ulasoglu C., Doganay L., Ozkanli S., Oltulu Y. M., Coskunpinar E., TUNCER İ.  
WORLD JOURNAL OF GASTROENTEROLOGY, vol.21, no.26, pp.8096-8102, 2015 (SCI-Expanded)
- XCIII. **Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease**  
ERGELEN R., Akyuz U., Aydin Y., EREN F., YILMAZ Y.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.27, no.6, pp.667-671, 2015 (SCI-Expanded)
- XCIV. **Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels**  
Akyuz U., Yesil A., YILMAZ Y.  
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.50, no.3, pp.341-346, 2015 (SCI-Expanded)
- XCV. **Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease**  
Subasi C. F., Aykut U. E., YILMAZ Y.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.27, no.2, pp.137-141, 2015 (SCI-Expanded)
- XCVI. **Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness.**  
Sünbül M., Agirbasli M., Durmus E., Kivrak T., Akin H., Aydin Y., Ergelen R., Yilmaz Y.

- Atherosclerosis, vol.237, no.2, pp.490-3, 2014 (SCI-Expanded)
- XCVII. **Can Enhanced Autophagy Be Associated with Human Longevity? Serum Levels of the Autophagy Biomarker Beclin-1 Are Increased in Healthy Centenarians**  
Emanuele E., Minoretti P., Sanchis-Gomar F., Pareja-Galeano H., YILMAZ Y., Garatachea N., Lucia A.  
REJUVENATION RESEARCH, vol.17, no.6, pp.518-524, 2014 (SCI-Expanded)
- XCVIII. **No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects**  
Yonal O., EREN F., YILMAZ Y., ATUĞ Ö., Over H. H.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.25, no.6, pp.639-643, 2014 (SCI-Expanded)
- XCIX. **ARE PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE AT INCREASED RISK OF ASTHMA? - RESULTS FROM A TURKISH CROSS-SECTIONAL STUDY**  
Tasli B., YILMAZ Y.  
RESPIROLOGY, vol.19, pp.189, 2014 (SCI-Expanded)
- C. **A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease**  
YILMAZ Y., EREN F.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.26, no.11, pp.1292-1295, 2014 (SCI-Expanded)
- CI. **A comparison of FibroMeter (TM) NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease**  
Aykut U. E., Akyuz U., Yesil A., EREN F., Gerin F., ERGELEN R., ÇELİKEL Ç., YILMAZ Y.  
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.49, no.11, pp.1343-1348, 2014 (SCI-Expanded)
- CII. **A Potential Treatment of Non-Alcoholic Fatty Liver Disease with SIRT1 Activators**  
ÇOLAK Y., Yesil A., MUTLU H. H., Caklili O. T., Ulasoglu C., SENATES E., Takir M., Kostek O., YILMAZ Y., Enc F. Y., et al.  
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, vol.23, no.3, pp.311-319, 2014 (SCI-Expanded)
- CIII. **Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis**  
Musso G., Gambino R., Tabibian J. H., Ekstedt M., Kechagias S., Hamaguchi M., Hultcrantz R., Hagstrom H., Yoon S. K., Charatcharoenwitthaya P., et al.  
PLOS MEDICINE, vol.11, no.7, 2014 (SCI-Expanded)
- CIV. **Letter: gut microbiota modulation contributes to coffee's benefits for non-alcoholic fatty liver disease - authors' reply**  
Yesil A., Yilmaz Y.  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.39, no.12, pp.1442, 2014 (SCI-Expanded)
- CV. **Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease**  
YILMAZ Y., Senates E., Yesil A., ERGELEN R., ÇOLAK Y.  
JOURNAL OF DIABETES AND ITS COMPLICATIONS, vol.28, no.3, pp.328-331, 2014 (SCI-Expanded)
- CVI. **Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy**  
YILMAZ Y., Yesil A., Gerin F., ERGELEN R., Akin H., ÇELİKEL Ç., Imeryuz N.  
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.49, no.5, pp.611-616, 2014 (SCI-Expanded)
- CVII. **Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease**  
YILMAZ Y., Ayyildiz T., Akin H., ÇOLAK Y., Ozturk O., Senates E., TUNCER İ., Dolar E.  
GUT AND LIVER, vol.8, no.3, pp.313-317, 2014 (SCI-Expanded)
- CVIII. **Obesity-Associated Nonalcoholic Fatty Liver Disease**  
YILMAZ Y., Younossi Z. M.  
CLINICS IN LIVER DISEASE, vol.18, no.1, pp.19-32, 2014 (SCI-Expanded)
- CIX. **Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease**  
Yesil A., Yilmaz Y.

- ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.38, no.9, pp.1038-1044, 2013 (SCI-Expanded)
- CX. **Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography**  
YILMAZ Y., ERGELEN R., Akin H., Imeryuz N.
- EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.25, no.11, pp.1330-1334, 2013 (SCI-Expanded)
- CXI. **Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials**  
YILMAZ Y.
- CURRENT DRUG TARGETS, vol.14, no.11, pp.1357-1366, 2013 (SCI-Expanded)
- CXII. **Liver disease and malnutrition**  
Purnak T., YILMAZ Y.
- BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, vol.27, no.4, pp.619-629, 2013 (SCI-Expanded)
- CXIII. **Assessment of endothelial function in patients with nonalcoholic fatty liver disease**  
Colak Y., Senates E., Yesil A., YILMAZ Y., Ozturk O., Doganay L., Coskunpinar E., Kahraman O. T., MESCİ B., Ulasoglu C., et al.  
ENDOCRINE, vol.43, no.1, pp.100-107, 2013 (SCI-Expanded)
- CXIV. **Letter: diagnostic accuracy of M30 levels for identifying patients with non-alcoholic steatohepatitis**  
Yilmaz Y.  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.37, no.2, pp.283, 2013 (SCI-Expanded)
- CXV. **Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back**  
YILMAZ Y., ÇOLAK Y., Kurt R., Senates E., EREN F.  
TUMORI, vol.99, no.1, pp.10-16, 2013 (SCI-Expanded)
- CXVI. **Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease**  
YILMAZ Y., Ozturk O., Alandab Y., Senates E., ÇOLAK Y., Doganay H. L., Coskunpinar E., Oltulu Y. M., EREN F., ATUĞ Ö., et al.  
DIGESTIVE AND LIVER DISEASE, vol.45, no.1, pp.58-62, 2013 (SCI-Expanded)
- CXVII. **Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis**  
YILMAZ Y., EREN F.  
CLINICA CHIMICA ACTA, vol.414, pp.154-157, 2012 (SCI-Expanded)
- CXVIII. **Hepatic expression and serum levels of syndecan 1 (CD 138) in patients with nonalcoholic fatty liver disease**  
YILMAZ Y., EREN F., ÇOLAK Y., Senates E., ÇELİKEL Ç., Imeryuz N.  
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.47, no.12, pp.1488-1493, 2012 (SCI-Expanded)
- CXIX. **Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?**  
Yilmaz Y.  
World Journal of Hepatology, vol.4, pp.332-334, 2012 (SCI-Expanded)
- CXX. **Research update for articles published in EJCI in 2010**  
Adlbrecht C., Aigner E., Bellon J. M., Bouloukaki I., Bouzas-Mosquera A., Carrilho A. J. F., Chang K., Chattipakorn N., Chattipakorn S. C., Chen Y., et al.  
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol.42, no.11, pp.1149-1164, 2012 (SCI-Expanded)
- CXXI. **Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?**  
Yilmaz Y.  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.36, no.9, pp.815-823, 2012 (SCI-Expanded)
- CXXII. **Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease**  
YILMAZ Y.  
CLINICA CHIMICA ACTA, vol.413, pp.1190-1193, 2012 (SCI-Expanded)

- CXXIII. **Review article: non-alcoholic fatty liver disease and osteoporosis - clinical and molecular crosstalk**  
Yilmaz Y.  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.36, no.4, pp.345-352, 2012 (SCI-Expanded)
- CXXIV. **Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease**  
Eren F., Kurt R., Ermis F., Atug Ö., Imeryuz N., Yilmaz Y.  
Clinical Biochemistry, vol.45, pp.655-658, 2012 (SCI-Expanded)
- CXXV. **Nonalcoholic Fatty Liver Disease: A Nutritional Approach**  
ÇOLAK Y., TUNCER İ., Senates E., Ozturk O., Doganay L., YILMAZ Y.  
METABOLIC SYNDROME AND RELATED DISORDERS, vol.10, no.3, pp.161-166, 2012 (SCI-Expanded)
- CXXVI. **Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis**  
YILMAZ Y., Yonal O., Deyneli O., ÇELİKEL Ç., Kalayci C., DUMAN D.  
ACTA GASTRO-ENTEROLOGICA BELGICA, vol.75, no.2, pp.240-244, 2012 (SCI-Expanded)
- CXXVII. **Review article: fructose in non-alcoholic fatty liver disease**  
Yilmaz Y.  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.35, pp.1135-1144, 2012 (SCI-Expanded)
- CXXVIII. **Unconjugated hyperbilirubinemia and liver histology in patients with non-alcoholic fatty liver disease**  
Kurt R., YILMAZ Y.  
CLINICAL BIOCHEMISTRY, vol.45, no.6, pp.515, 2012 (SCI-Expanded)
- CXXIX. **Circulating vaspin and its relationship with insulin sensitivity, adiponectin and liver histology in subjects with non-alcoholic steatohepatitis**  
YILMAZ Y.  
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.47, no.4, pp.489-490, 2012 (SCI-Expanded)
- CXXX. **Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome**  
YILMAZ Y., Senates E., Ayyildiz T., Colak Y., Tuncer I., Ovunc A. O. K., Dolar E., Kalayci C.  
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol.42, no.4, pp.411-418, 2012 (SCI-Expanded)
- CXXXI. **Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology**  
Colak Y., Senates E., Ozturk O., YILMAZ Y., Zemheri E., Enc F. Y., Ulasoglu C., Aksaray S., Bozbeyoglu S. G., Kiziltas S., et al.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.24, no.3, pp.255-261, 2012 (SCI-Expanded)
- CXXXII. **Is M65 really better than M30 as a biomarker of hepatic fibrosis?**  
YILMAZ Y., Kurt R.  
HEPATOLOGY, vol.55, no.2, pp.654, 2012 (SCI-Expanded)
- CXXXIII. **NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Factors for Disease Progression?**  
YILMAZ Y.  
SEMINARS IN LIVER DISEASE, vol.32, no.1, pp.14-21, 2012 (SCI-Expanded)
- CXXXIV. **Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis**  
ÇOLAK Y., Senates E., Coskunpinar E., Oltulu Y. M., Zemheri E., Ozturk O., Doganay L., MESCI B., YILMAZ Y., Enc F. Y., et al.  
DISEASE MARKERS, vol.33, no.2, pp.77-83, 2012 (SCI-Expanded)
- CXXXV. **Preliminary evidence of an association between the functional c-kit rs6554199 polymorphism and achalasia in a Turkish population**  
Alahdab Y., Eren F., Giral A., Gunduz F., Kedrah A. E., Atug O., Yilmaz Y., Kalayci O., Kalayci C.  
NEUROGASTROENTEROLOGY AND MOTILITY, vol.24, no.1, pp.27-30, 2012 (SCI-Expanded)
- CXXXVI. **The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy**

- Atasoy B. M., Yonal O., Demirel B., DANE F., YILMAZ Y., Kalayci C., Abacioglu U., Imeryuz N.  
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, vol.269, no.1, pp.275-282, 2012 (SCI-Expanded)
- CXXXVII. **Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration**  
YILMAZ Y., Kurt R., EREN F., Imeryuz N.  
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, vol.71, no.8, pp.631-636, 2011 (SCI-Expanded)
- CXXXVIII. **A Glance at the methods for detection of apoptosis qualitatively and quantitatively Apoptozun nitel ve niceł olarak tespitine yönelik metotlara ki{dotless}sa bir baki{dotless}ş**  
Ulukaya E., Acilan C., Ari F., Ikitimur E., Yilmaz Y.  
Turkish Journal of Biochemistry, vol.36, pp.261-269, 2011 (SCI-Expanded)
- CXXXIX. **Cytokeratins in hepatitis**  
YILMAZ Y.  
CLINICA CHIMICA ACTA, vol.412, pp.2031-2036, 2011 (SCI-Expanded)
- CXL. **Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis**  
YILMAZ Y., EREN F., Ayyildiz T., Colak Y., Kurt R., Senates E., Tuncer I., Dolar E., Imeryuz N.  
CLINICA CHIMICA ACTA, vol.412, pp.2296-2299, 2011 (SCI-Expanded)
- CXLI. **Plasma Fibrinogen-Like Protein 2 Levels in Patients with Non-Alcoholic Fatty Liver Disease**  
Colak Y., Senates E., Ozturk O., YILMAZ Y., Coskunpinar E., Kahraman O. T., Sahin O., Zemheri E., Enc F. Y., Ulasoglu C., et al.  
HEPATO-GASTROENTEROLOGY, vol.58, no.112, pp.2087-2090, 2011 (SCI-Expanded)
- CXLII. **Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity**  
Yilmaz Y., Yonal O., Eren F., Atug O., Hamzaoglu H. O.  
Journal of Crohn's and Colitis, vol.5, no.5, pp.402-406, 2011 (SCI-Expanded)
- CXLIII. **Association Between The Presence of Brown Adipose Tissue and Nonalcoholic Fatty Liver Disease in Adult Humans**  
Yilmaz Y., Ones T., Purnak T., Kurt R., Ozguven S., Atug O., Turoglu H., Imeryuz N.  
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)
- CXLIV. **Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans.**  
Yilmaz Y., Ones T., Purnak T., Ozguven S., Kurt R., Atug O., Turoglu H. T., Imeryuz N.  
Alimentary pharmacology & therapeutics, vol.34, no.3, pp.318-23, 2011 (SCI-Expanded)
- CXLV. **Serum galectin-3 levels in patients with nonalcoholic fatty liver disease**  
YILMAZ Y., EREN F., Kurt R., Yonal O., Polat Z., Senates E., Bacha M., Imeryuz N.  
CLINICAL BIOCHEMISTRY, vol.44, no.12, pp.955-958, 2011 (SCI-Expanded)
- CXLVI. **Apoptosis: why and how does it occur in biology?**  
ULUKAYA E., Acilan C., YILMAZ Y.  
CELL BIOCHEMISTRY AND FUNCTION, vol.29, no.6, pp.468-480, 2011 (SCI-Expanded)
- CXLVII. **Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease**  
Senates E., YILMAZ Y., Colak Y., Ozturk O., Altunoz M. E., Kurt R., Ozkara S., Aksaray S., Tuncer I., Ovunc A. O. K.  
METABOLIC SYNDROME AND RELATED DISORDERS, vol.9, no.4, pp.287-290, 2011 (SCI-Expanded)
- CXLVIII. **Multimarker Strategies for Detecting NASH and NASH-Related Fibrosis: Promises and Caveats**  
YILMAZ Y., Kurt R., EREN F.  
OBESITY SURGERY, vol.21, no.8, pp.1316-1317, 2011 (SCI-Expanded)
- CXLIX. **Author's Reply; Noninvasive tests of fibrosis: To get the right answers, we need to ask the right questions**  
Yilmaz Y., Kurt R.  
Hepatitis Monthly, vol.11, no.8, pp.668-670, 2011 (SCI-Expanded)
- CL. **Author's Reply; Noninvasive Tests of Fibrosis: To Get the Right Answers, We Need to Ask the Right**

## **Questions**

YILMAZ Y., Kurt R.

HEPATITIS MONTHLY, vol.11, no.8, pp.669-670, 2011 (SCI-Expanded)

- CLI. **Authors' Reply: Noninvasive liver fibrosis assessment; Why does the APRI not work for Hepatitis B?**

YILMAZ Y., Yonal O., Kurt R.

HEPATITIS MONTHLY, vol.11, no.7, pp.557, 2011 (SCI-Expanded)

- CLII. **Reply to Aydin et al: "To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?"**

Yilmaz Y., Eren F.

Metabolism: Clinical and Experimental, vol.60, 2011 (SCI-Expanded)

- CLIII. **Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease**

YILMAZ Y., Kurt R., Gurdal A., ÖZEN ALAHDAB Y., Yonal O., Senates E., Polat N., EREN F., Imeryuz N., Oflaz H.

ATHEROSCLEROSIS, vol.217, no.1, pp.125-129, 2011 (SCI-Expanded)

- CLIV. **Kefir Improves the Efficacy and Tolerability of Triple Therapy in Eradicating Helicobacter pylori**

Bekar O., YILMAZ Y., Gulten M.

JOURNAL OF MEDICINAL FOOD, vol.14, no.4, pp.344-347, 2011 (SCI-Expanded)

- CLV. **Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease**

Aktas B., YILMAZ Y., EREN F., Yonal O., Kurt R., Alandab Y., ÇELİKEL Ç., Ozdogan O., Imeryuz N., Kalayci C., et al.

METABOLISM-CLINICAL AND EXPERIMENTAL, vol.60, no.4, pp.544-549, 2011 (SCI-Expanded)

- CLVI. **Toward a Biochemical Diagnosis of NASH: Insights From Pathophysiology For Distinguishing Simple Steatosis From Steatohepatitis**

Yilmaz Y., Ulukaya E.

CURRENT MEDICINAL CHEMISTRY, vol.18, no.5, pp.725-732, 2011 (SCI-Expanded)

- CLVII. **Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease**

YILMAZ Y., Yonal O., Kurt R., Bayrak M., Aktas B., Ozdogan O.

HEPATITIS MONTHLY, vol.11, no.2, pp.103-107, 2011 (SCI-Expanded)

- CLVIII. **Serum programulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease**

Yilmaz Y., Eren F., Yonal O., Polat Z., Bacha M., Kurt R., Ozturk O., Avsar E.

Disease Markers, vol.31, pp.205-210, 2011 (SCI-Expanded)

- CLIX. **Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy.**

Ari E., Yilmaz Y., Kedrah A. E., Alahdab Y., Cakalagaoglu F., Arikan H., Koçak H., Macunluoglu B., Atakan A., Kahveci A., et al.

American journal of nephrology, vol.33, no.3, pp.269-76, 2011 (SCI-Expanded)

- CLX. **Serum zinc-alpha(2)-glycoprotein concentrations in patients with non-alcoholic fatty liver disease**

Yilmaz Y., Yonal O., Eren F., Kurt R., Celikel Ç., Ozdogan O., Imeryuz N., Kalayci C., Avsar E.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, vol.49, no.1, pp.93-97, 2011 (SCI-Expanded)

- CLXI. **Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease**

Yilmaz Y., Yonal O., Kurt R., Alahdab Y., Ozdogan O., Celikel Ç., Ulukaya E., Imeryuz N., Kalayci C., Avsar E.

ARCHIVES OF MEDICAL RESEARCH, vol.42, no.1, pp.38-43, 2011 (SCI-Expanded)

- CLXII. **Serum levels of omentin, chemerin and adiponectin in patients with biopsy-proven nonalcoholic fatty liver disease**

Yilmaz Y., Yonal O., Kurt R., Alahdab Y., Eren F., Ozdogan O., Celikel Ç., Imeryuz N., Kalayci C., Avsar E.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.46, no.1, pp.91-97, 2011 (SCI-Expanded)

- CLXIII. **Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B**

EREN F., YILMAZ Y., Kose S., Ozdemir F. T., Yonal O., Kurt R., Ozdogan O., Avsar E.

CLINICA CHIMICA ACTA, vol.411, pp.2029-2032, 2010 (SCI-Expanded)

- CLXIV. Liver Enzymes and Cardiovascular Outcomes a New Research Agenda**  
YILMAZ Y., Kuri R., Kalayci C.  
HEPATOLOGY, vol.52, no.6, pp.2242, 2010 (SCI-Expanded)
- CLXV. Liver function tests: Association with cardiovascular outcomes**  
Yilmaz Y.  
World Journal of Hepatology, vol.2, pp.143-145, 2010 (SCI-Expanded)
- CLXVI. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease**  
Yilmaz Y., Yonal O., Kurt R., Oral A. Y., Eren F., Ozdogan O., Ari F., Çelikel Ç., Korkmaz S., Ulukaya E., et al.  
Scandinavian Journal of Clinical and Laboratory Investigation, vol.70, pp.541-546, 2010 (SCI-Expanded)
- CLXVII. Serum fetuin A/alpha 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis**  
YILMAZ Y., Yonal O., Kurt R., ARI F., YILMAZTEPE ORAL A., ÇELİKEL Ç., KORKMAZ Ş., ULUKAYA E., Ozdogan O., Imeryuz N., et al.  
ANNALS OF CLINICAL BIOCHEMISTRY, vol.47, pp.549-553, 2010 (SCI-Expanded)
- CLXVIII. Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments**  
YILMAZ Y., Kurt R., Kalayci C.  
BIOMARKERS IN MEDICINE, vol.4, no.5, pp.743-745, 2010 (SCI-Expanded)
- CLXIX. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease**  
YILMAZ Y., Eren F., Yonal O., Kurt R., Aktas B., ÇELİKEL Ç., Ozdogan O., Imeryuz N., Kalayci C., Avsar E.  
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol.40, no.10, pp.887-892, 2010 (SCI-Expanded)
- CLXX. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis**  
YILMAZ Y., Alahdab Y., Yonal O., Kurt R., Kedrah A. E., ÇELİKEL Ç., Ozdogan O., DUMAN D., Imeryuz N., Avsar E., et al.  
METABOLISM-CLINICAL AND EXPERIMENTAL, vol.59, no.9, pp.1327-1330, 2010 (SCI-Expanded)
- CLXXI. Microalbuminuria and nonalcoholic fatty liver disease**  
Yilmaz Y., Alahdab Y. O., Yonal O., Imeryuz N., Kalayci C.  
Metabolism: Clinical and Experimental, vol.59, 2010 (SCI-Expanded)
- CLXXII. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis**  
YILMAZ Y., Kurt R., Yonal O., Polat N., ÇELİKEL Ç., Gurdal A., Oflaz H., Ozdogan O., Imeryuz N., Kalayci C., et al.  
ATHEROSCLEROSIS, vol.211, no.1, pp.182-186, 2010 (SCI-Expanded)
- CLXXIII. Folic Acid and Vitamin B12 Supplementation Improves Coronary Flow Reserve in Elderly Subjects with Vitamin B12 Deficiency**  
Kurt R., YILMAZ Y., Ermis F., Besik S. K., Polat N., Elitok A., Oflaz H., Karan M. A.  
ARCHIVES OF MEDICAL RESEARCH, vol.41, no.5, pp.369-372, 2010 (SCI-Expanded)
- CLXXIV. The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts**  
Yilmaz Y.  
JOURNAL OF GASTROENTEROLOGY, vol.45, no.7, pp.782-783, 2010 (SCI-Expanded)
- CLXXV. Cigarette Smoking Is Not Associated with Specific Histological Features or Severity of Nonalcoholic Fatty Liver Disease**  
YILMAZ Y., Yonai O., Kurt R., Avsar E.  
HEPATOLOGY, vol.52, no.1, pp.391, 2010 (SCI-Expanded)
- CLXXVI. The Impact of Prophylactic Percutaneus Endoscopic Gastrostomy to Nutritional Status and Quality of Life in Locally Advanced Head and Neck Cancer Patients Receiving Chemoradiotherapy**  
Yonal O., Atasoy B. M., Demirel B., YILMAZ Y., Dane F., ABACIOGLU M. U., Kalayci C., Imeryuz N.  
GASTROENTEROLOGY, vol.138, no.5, 2010 (SCI-Expanded)
- CLXXVII. Molecular Signatures of Nonalcoholic Fatty Liver Disease: The Present and Future**  
YILMAZ Y., ULUKAYA E.  
HEPATOLOGY, vol.51, no.5, pp.1866, 2010 (SCI-Expanded)

- CLXXVIII. C-KIT Gene Polymorphism in Achalasia**  
Alahdab Y. O., EREN F., Gunduz F., Kedrah A. E., YILMAZ Y., Atug O., Imeryuz N., Giral A., Avsar E., Kalayci C.  
*GASTROENTEROLOGY*, vol.138, no.5, 2010 (SCI-Expanded)
- CLXXIX. Microalbuminuria in Nondiabetic Patients With Nonalcoholic Fatty Liver Disease: Association With Liver Fibrosis**  
YILMAZ Y., Alahdab Y. O., Yonal O., Kurt R., Kedrah A. E., Celikel Ç., Duman D., Ozdogan O., Imeryuz N., Avsar E., et al.  
*GASTROENTEROLOGY*, vol.138, no.5, 2010 (SCI-Expanded)
- CLXXX. Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis**  
Olmez O. F., Gurel S., YILMAZ Y.  
*EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY*, vol.22, no.4, pp.461-465, 2010 (SCI-Expanded)
- CLXXXI. M30 levels and nonalcoholic steatohepatitis in polycystic ovary syndrome**  
Yilmaz Y., Kurt R.  
*Journal Of Clinical Endocrinology*, vol.0, no.0, 2010 (SCI-Expanded)
- CLXXXII. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients**  
Gul O. O., Tuncel E., YILMAZ Y., ULUKAYA E., Gul C. B., Kiyici S., YILMAZTEPE ORAL A., Guclu M., ERSOY C., Imamoglu S.  
*METABOLISM-CLINICAL AND EXPERIMENTAL*, vol.59, no.1, pp.64-69, 2010 (SCI-Expanded)
- CLXXXIII. Metformin, hepatitis C, and insulin resistance: Sufficient evidence?**  
Yilmaz Y., Yonal O., Imeryuz N.  
*Hepatology*, vol.50, pp.2054-2055, 2009 (SCI-Expanded)
- CLXXXIV. Systematic review: Caspase-cleaved fragments of cytokeratin 18 - The promises and challenges of a biomarker for chronic liver disease**  
Yilmaz Y.  
*Alimentary Pharmacology and Therapeutics*, vol.30, pp.1103-1109, 2009 (SCI-Expanded)
- CLXXXV. Familial Mediterranean Fever coexisting with celiac disease: Is there a link with long-term colchicine treatment?**  
Yilmaz Y., Baran B., Seniz N. B., Dolar E.  
*Journal of Gastrointestinal and Liver Diseases*, vol.18, pp.119-120, 2009 (SCI-Expanded)
- CLXXXVI. Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: Relationship with the severity of coronary artery disease**  
Senturk T., Aydinlar A., Yilmaz Y., Yilmaztepe Oral A., Ozdabakoglu O., Ulukaya E.  
*Coronary Artery Disease*, vol.20, pp.494-498, 2009 (SCI-Expanded)
- CLXXXVII. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients**  
Arabul M., Gullulu M., Yilmaz Y., Eren M. A., Baran B., Gul C. B., Kocamaz G., Dilek K.  
*Medical Science Monitor*, vol.15, 2009 (SCI-Expanded)
- CLXXXVIII. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: Association with insulin resistance**  
Yilmaz Y., Ulukaya E., Atug Ö., Dolar E.  
*European Journal of Gastroenterology and Hepatology*, vol.21, pp.1247-1251, 2009 (SCI-Expanded)
- CLXXXIX. Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count.**  
Ari E., YILMAZ Y., Gul A., ÖZEN ALAHDAB Y., Kedrah A. E., Macunluoglu B., Aydin A., Arikan H., Ozener C.  
*American journal of reproductive immunology (New York, N.Y. : 1989)*, vol.62, no.4, pp.238-42, 2009 (SCI-Expanded)
- CXC. Non-alcoholic fatty liver disease and microalbuminuria in non-diabetic patients: Role of insulin resistance**  
Yilmaz Y., Alahdab Y., Özdoğan O. C., Dolar E.  
*Internal Medicine Journal*, vol.39, pp.709-710, 2009 (SCI-Expanded)
- CXCI. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis.**

- YILMAZ Y., Kedrah A. E., Ozdogan O. C.  
 World journal of gastroenterology, vol.15, no.35, pp.4387-91, 2009 (SCI-Expanded)
- CXCII. **Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or decorations?**  
 YILMAZ Y., Dolar E.  
 WORLD JOURNAL OF GASTROENTEROLOGY, vol.15, no.34, pp.4346-4347, 2009 (SCI-Expanded)
- CXCIII. **Commentary on "Cytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Disease"**  
 YILMAZ Y., Dolar E., ULUKAYA E.  
 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, vol.49, no.3, pp.371, 2009 (SCI-Expanded)
- CXCIV. **"Defragmenting" the Noninvasive Diagnosis of Nonalcoholic Steatohepatitis: Hopes from Cytokeratin-18**  
 Yilmaz Y.  
 HEPATOLOGY, vol.50, no.3, pp.990-991, 2009 (SCI-Expanded)
- CXCV. **The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond**  
 Yilmaz Y., Ulukaya E., Dolar E.  
 Hepatology, vol.49, pp.1056-1057, 2009 (SCI-Expanded)
- CXCVI. **Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels**  
 Yilmaz Y., Ulukaya E., Dolar E.  
 Hepatology, vol.49, pp.697, 2009 (SCI-Expanded)
- CXCVII. **Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C**  
 ATUĞ Ö., Akin H., YILMAZ Y., Sari M., Tozun N.  
 JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, vol.18, no.2, pp.256, 2009 (SCI-Expanded)
- CXCVIII. **Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease**  
 YILMAZ Y., ULUKAYA E., Gul O. O., Arabul M., Gul C. B., ATUĞ Ö., YILMAZTEPE ORAL A., Aker S., Dolar E.  
 CLINICAL BIOCHEMISTRY, vol.42, no.9, pp.802-807, 2009 (SCI-Expanded)
- CXCIX. **Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C**  
 Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., Yerci O., Oral A. Y., Gul C. B., Gurel S., et al.  
 Medical Science Monitor, vol.15, 2009 (SCI-Expanded)
- CC. **Coronary artery anomalies in patients with syndrome X**  
 Akgüllü Ç., Yilmaz Y., Yücel E., Kaderli A. A., Kumbay E., Ayndinlar A.  
 Anadolu Kardiyoloji Dergisi, vol.9, pp.69, 2009 (SCI-Expanded)
- CCI. **Serum Levels of Adipokines in Patients with Chronic HCV Infection: Relationship with Steatosis and Fibrosis**  
 Tiftikci A., ATUĞ Ö., YILMAZ Y., EREN F., Ozdemir F. T., Yapali S., Ozdogan O., ÇELİKEL Ç., Imeryuz N., Tozun N.  
 ARCHIVES OF MEDICAL RESEARCH, vol.40, no.4, pp.294-298, 2009 (SCI-Expanded)
- CCII. **Dipeptidyl peptidase IV inhibitors: Therapeutic potential in nonalcoholic fatty liver disease**  
 YILMAZ Y., ATUĞ Ö., Yonal O., DUMAN D., Ozdogan O., Imeryuz N., Kalayci C.  
 MEDICAL SCIENCE MONITOR, vol.15, no.4, 2009 (SCI-Expanded)
- CCIII. **Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: Relation to disease severity**  
 Keskin M., Dolar E., Dirican M., Kiyici M., Yilmaz Y., Gurel S., Nak S., Erdinc S., Gulten M.  
 Internal Medicine Journal, vol.39, pp.243-248, 2009 (SCI-Expanded)
- CCIV. **Liver Disease as a Risk Factor for Cognitive Decline and Dementia: an Under-Recognized Issue**  
 YILMAZ Y., Ozdogan O.  
 HEPATOLOGY, vol.49, no.2, pp.698, 2009 (SCI-Expanded)
- CCV. **Acute arsenic self-poisoning for suicidal purpose in a dentist: A case report**

- Yilmaz Y., Armagan E., Olmez O., Esen M., Alkis N., Dolar E.  
Human and Experimental Toxicology, vol.28, pp.63-65, 2009 (SCI-Expanded)
- CCVI. **Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry**  
ULUKAYA E., YILMAZ Y., Moshkovskii S., Karpova M., Pyatnitskiy M., ATUĞ Ö., Dolar E.  
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.44, no.12, pp.1471-1476, 2009 (SCI-Expanded)
- CCVII. **Small arterial elasticity predicts the extent of coronary artery disease: Relationship with serum uric acid**  
Fazlioğlu M., Şentürk T., Kumbay E., Kaderli A. A., Yilmaz Y., Özdemir B., Baran I., Aydinlar A.  
Atherosclerosis, vol.202, pp.200-204, 2009 (SCI-Expanded)
- CCVIII. **Predictive value of the modified early warning score in a turkish emergency department**  
Armagan E., Yilmaz Y., Olmez O. F., Simsek G., Gul C. B.  
European Journal of Emergency Medicine, vol.15, pp.338-340, 2008 (SCI-Expanded)
- CCIX. **Concomitant colitis in a patient with Behcet's disease**  
Yilmaz Y., Dolar E.  
Journal of Gastrointestinal and Liver Diseases, vol.17, no.4, pp.481-483, 2008 (SCI-Expanded)
- CCX. **A "biomarker biopsy" for the diagnosis of NASH: Promises from CK-18 fragments**  
Yilmaz Y., Ulukaya E., Dolar E.  
Obesity Surgery, vol.18, pp.1507-1508, 2008 (SCI-Expanded)
- CCXI. **Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease**  
Arabul M., Gullulu M., Yilmaz Y., Akdag I., Kahvecioglu S., Ali Eren M., Dilek K.  
Clinical Biochemistry, vol.41, pp.1055-1058, 2008 (SCI-Expanded)
- CCXII. **The Pro12Ala polymorphism of peroxisome proliferator-activated receptor- $\gamma$ 2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease**  
Catalano M., Cortelazzo A., Santi R., Contino L., Demicheli M., Yilmaz Y., Zorzetto M., Campo I., Lanati N., Emanuele E.  
Clinical Biochemistry, vol.41, pp.981-985, 2008 (SCI-Expanded)
- CCXIII. **Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease**  
Akgullu C., Ozdemir B., Yilmaz Y., Kazazoglu A. R., Aydinlar A.  
Acta Cardiologica, vol.63, no.4, pp.467-471, 2008 (SCI-Expanded)
- CCXIV. **Helicobacter pylori: A role in schizophrenia?**  
Yilmaz Y., Gul C. B., Arabul M., Eren M. A.  
Medical Science Monitor, vol.14, 2008 (SCI-Expanded)
- CCXV. **Apical ballooning syndrome: A metabolic form of cardiomyopathy?**  
Yilmaz Y.  
Medical Science Monitor, vol.14, 2008 (SCI-Expanded)
- CCXVI. **Urinary IL-18: A marker of contrast-induced nephropathy following percutaneous coronary intervention?**  
Bulent Gul C., Gullulu M., Oral B., Aydinlar A., Oz O., Budak F., Yilmaz Y., Yurtkuran M.  
Clinical Biochemistry, vol.41, pp.544-547, 2008 (SCI-Expanded)
- CCXVII. **Acute myocardial infarction, ischemic cerebrovascular disease and variceal bleeding due to portal vein thrombosis in a patient with hereditary thrombophilia**  
Baran B., Yilmaz Y., Algin O., Keskin M., Kiyici M., Kocamaz G., Dolar E.  
Blood Coagulation and Fibrinolysis, vol.19, pp.243-246, 2008 (SCI-Expanded)
- CCXVIII. **The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease**  
Falcone C., Geroldi D., Buzzi M. P., Emanuele E., Yilmaz Y., Fontana J. M., Vignali L., Boiocchi C., Sbarsi I., Cuccia M.  
Archives of Medical Research, vol.39, pp.320-325, 2008 (SCI-Expanded)
- CCXIX. **Psychopathology in the context of obesity: The adiponectin hypothesis**  
Yilmaz Y.  
Medical Hypotheses, vol.70, pp.902-903, 2008 (SCI-Expanded)

- CCXX. **Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: A 5-year prospective study**  
 Akdag I., Yilmaz Y., Kahvecioglu S., Bolca N., Ercan I., Ersoy A., Gullulu M.  
*Nephron - Clinical Practice*, vol.108, 2008 (SCI-Expanded)
- CCXXI. **The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease**  
 Catalano M., Cortelazzo A., Yilmaz Y., Perilli E., Carzaniga G., Emanuele E.  
*Clinica Chimica Acta*, vol.387, pp.109-112, 2008 (SCI-Expanded)
- CCXXII. **Evaluation of leukocyte esterase and nitrite strip tests to detect spontaneous bacterial peritonitis in cirrhotic patients**  
 Torun S., Dolar E., Yilmaz Y., Keskin M., Kiyici M., Sinirtas M., Sarandol E., Gurel S., Nak S. G., Gulten M.  
*World Journal of Gastroenterology*, vol.13, pp.6027-6030, 2007 (SCI-Expanded)
- CCXXIII. **Clinical significance of activity of ALT enzyme in patients with hepatitis C virus**  
 Akkaya O., Kiyici M., Yilmaz Y., Ulukaya E., Yerci O.  
*World Journal of Gastroenterology*, vol.13, pp.5481-5485, 2007 (SCI-Expanded)
- CCXXIV. **Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis**  
 Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., Aker S., Yilmaztepe A., Gurel S., Gulten M., et al.  
*World Journal of Gastroenterology*, vol.13, pp.837-844, 2007 (SCI-Expanded)

## Articles Published in Other Journals

- I. **TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease**  
 YILMAZ Y., ZEYBEL M., ADALI G., COŞAR A., SERTESEN E., SÜMER H., BAHCECİOĞLU İ. H., ŞAHİN M., KAYA C. T., ERGÜN İ., et al.  
*Hepatology forum*, vol.4, no.1, pp.1-32, 2023 (Scopus)
- II. **Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan**  
 Yesil E. E., YILMAZ Y., Yesil A., Mese M., Kaya E., Bakir E. A.  
*HEPATOLOGY FORUM*, vol.4, no.1, pp.14-18, 2023 (ESCI)
- III. **Insidious danger for young adults: Metabolic (dysfunction)associated fatty liver disease**  
 Kaya E., YILMAZ Y.  
*HEPATOLOGY FORUM*, vol.3, no.2, pp.39-40, 2022 (ESCI)
- IV. **Prevention of hepatocellular carcinoma and surveillance of high risk patients**  
 Kaya E., Mazzolini G. D., YILMAZ Y., CANBAY A.  
*Hepatology Forum*, vol.3, pp.33-38, 2022 (ESCI)
- V. **Demographic Characteristics and Transmission Risk Factors of Patients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial**  
 TABAK F., ŞİRİN G., DEMİR M., ALADAĞ M., SÜMER Ş., KURTARAN B., TOSUN S., YAMAZHAN T., BOZKURT İ., GÜRBÜZ Y., et al.  
*Viral Hepatitis Journal*, vol.27, no.3, pp.109-117, 2021 (ESCI)
- VI. **The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study**  
 YILMAZ Y., YILMAZ N., ATEŞ F., KARAKAYA F., GÖKCAN H., KAYA E., ADALI G., ÇALIŞKAN KARTAL A., ŞEN İ., AHİSHALI E., et al.  
*Hepatology Forum*, vol.2, no.2, pp.37-42, 2021 (ESCI)
- VII. **Comparison of aerobic and combined aerobic and whole-body vibration training effects on physical fitness in non-alcoholic fatty liver patients**  
 Saldırın T. C., Mutluay F. K., Yagci İ., Yilmaz Y.

- COMPARATIVE EXERCISE PHYSIOLOGY, vol.17, no.4, pp.393-401, 2021 (ESCI)
- VIII. **High incidence of hepatitis B core antibody positivity in metabolic-associated fatty liver disease-related cirrhosis**  
ERGENÇ İ., GÖKÇEN P., ADALI G., Kani H. T., Demirtaş C. Ö., Gündüz F., Çelikel Ç. A., YILMAZ Y.  
Hepatology Forum, vol.1, no.2, pp.20-25, 2021 (ESCI)
- IX. **The clinical and histological characteristics of patients with biopsy-proven non-alcoholic fatty liver disease in the absence of insulin resistance**  
DEMİRTAŞ C. Ö., SAPMAZ A., GÜREL B. A., KIZMAZ H., ULU T., KARAKETİR Ş. G., YILMAZ Y.  
Hepatology Forum, vol.1, no.3, pp.101-108, 2020 (Peer-Reviewed Journal)
- X. **Regular coffee intake improves liver enzyme levels and liver histology in patients with chronic alcohol consumption, non-alcoholic fatty liver and non-alcoholic steatohepatitis: Report of 259 cases**  
DEĞERTEKİN M. B., TÖZÜN A. N., Söylemez A. G., Gurtay E., Bozkurt U., YILMAZ Y., YAPALI S., VARDARELİ N. E., ÜNAL H. Ü., Çolakoğlu B., et al.  
Hepatology Forum, vol.1, no.3, pp.88-96, 2020 (Peer-Reviewed Journal)
- XI. **Metabolic-associated Fatty Liver Disease: Time to integrate ground-breaking new terminology to our clinical practice?**  
DEMİRTAŞ C. Ö., YILMAZ Y.  
Hepatology Forum, vol.1, no.3, pp.79-81, 2020 (Peer-Reviewed Journal)
- XII. **The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases**  
Kaya E., Bakır A., Eren F., Yılmaz Y.  
Hepatology Forum, vol.1, no.1, pp.8-13, 2020 (Peer-Reviewed Journal)
- XIII. **The comparison of resting metabolic rate between biopsy-proven non-alcoholic steatohepatitis and non-alcoholic fatty liver patients**  
KENGİR E. B., GÜVELİ H., Ergun C., Kaya E., YILMAZ Y.  
Hepatology Forum, vol.1, no.1, pp.14-19, 2020 (Peer-Reviewed Journal)
- XIV. **Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter**  
Kani H. T., Deliktaş I., YILMAZ Y.  
MARMARA MEDICAL JOURNAL, vol.32, no.2, pp.68-70, 2019 (ESCI)
- XV. **A Glance at the methods for detection of apoptosis qualitatively and quantitatively**  
Ulukaya E., Açılan C., Arı F., Elif İlkay İ., Yılmaz Y.  
A Glance at the methods for detection of apoptosis qualitatively and quantitatively, vol.36, pp.261-269, 2011 (Peer-Reviewed Journal)

## Books & Book Chapters

- I. **Covid-19 ve Karaciğer Yağlanması İlişkisi Nasıl Gelişmektedir?**  
Demirtaş C. Ö., YILMAZ Y.  
in: Türkiye Klinikleri Gastroenteroloji ve Covid-19, Ahmet Uygun, Editor, Türkiye Klinikleri, Ankara, pp.39-44, 2021
- II. **Non-alcoholic Fatty Liver Disease: A Global Public Health Issue**  
Kaya E., Yılmaz Y.  
in: Obesity and Diabetes, Joel Faintuch, Salomão Faintuc, Editor, Springer-Verlag, Zürich, pp.1-987, 2020
- III. **Alkol Dışı Yağlı Karaciğer Hastalığı**  
KEFELİ A., YILMAZ Y.  
in: Hepatobiliyer Sistem ve Pankreas Hastalıkları, Kefeli, Ayşe, Editor, Akademisyen Yayınevi, Ankara, pp.193-209, 2020
- IV. **Non-alcoholic Fatty Liver Disease: A Global Public Health Issue**  
KAYA E., YILMAZ Y.  
in: Obesity and Diabetes, Faintuch, Joel, Faintuch, Salomão, Editor, Springer, pp.321-333, 2020

- V. **Epidemiology of Nonalcoholic Fatty Liver Disease in Turkey and in the World**  
Kaya E., Yilmaz Y.  
in: Türkiye Klinikleri Gastroenterohepatoloji-Özel Konular: Nonalkolik Yağlı Karaciğer Hastalığı, Abdullah Sonsuz, Editor, Türkiye Klinikleri (Ortadoğu Reklam Tanıtım Yayıncılık), Ankara, pp.1-7, 2019
- VI. **Türkiye'de ve Dünyada Nonalkolik Yağlı Karaciğer Hastalığı Epidemiyolojisi**  
Kaya E., YILMAZ Y.  
in: Türkiye Klinikleri Gastroenterohepatoloji-Özel Konular Nonalkolik Yağlı Karaciğer Hastalığı, Abdullah Sonsuz, Editor, Türkiye Klinikleri (Ortadoğu Reklam Tanıtım Yayıncılık), Ankara, pp.1-7, 2019
- VII. **Is NAFLD different in absence of metabolic syndrome?**  
Yilmaz Y.  
in: Clinical Dilemmas in Non Alcoholic Fatty Liver Disease, Roger Williams, Simon D. Taylor-Robinson, Editor, Wiley-VCH Verlag Weinheim GmbH , London, pp.50-57, 2016
- VIII. **Obesity-Associated Nonalcoholic Fatty Liver Disease**  
YILMAZ Y., YOUNOSSI Z. M.  
in: OBESITY A Multidisciplinary Approach, Joel J. Heidelbaugh, Editor, ELSEVIER, Philadelphia, pp.93-107, 2015

### Refereed Congress / Symposium Publications in Proceedings

- I. **ANALYSIS OF THE EFFICACY OF A HIGHER DAILY ARAMCHOL DOSE ON FIBROSIS IMPROVEMENT IN THE ARMOR STUDY OPEN LABEL PART**  
Gorfine T., Ratziu V., YILMAZ Y., Friedman S. L., Hayardeny L., Kadosh S., Sanyal A. J.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 12 November 2021
- II. **Development and validation of Agile 4 and Agile 3+: Novel FibroScan based scores for the diagnosis of cirrhosis and advanced fibrosis in patients with non-alcoholic fatty liver disease**  
YILMAZ Y.  
French Hepatology congress (AFEF) 29 Eylül 2021-02 Ekim 2021, Biarritz, France, 07 July 2021
- III. **The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry**  
YOUNOSSI Z. M., YILMAZ Y., El Kassas M., Duseja A. K., Saeed H., Gammal E., Mendez-Sanchez N., CHAN W. K., Ashwani S., Brian L., et al.  
International Liver Congress (EASL), Roma, Italy, 23 June 2021, vol.75, pp.655
- IV. **Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease**  
YOUNOSSI Z. M., Harrison S. A., Newsome P. N., CHAN W. K., YILMAZ Y., Ledinghen V. d., Costentin C., Zheng M., Wong V. W., Elkhashab M., et al.  
International Liver Congress (EASL), Roma, Italy, 23 - 26 June 2021, vol.75, pp.257
- V. **Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosis**  
YILMAZ Y.  
International Liver Congress (EASL), Roma, Italy, 23 June 2021, vol.75, pp.259-260
- VI. **The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge?**  
Lazarus J., Mark H., Palayew A., Patrizia C., Colombo M., Ekstedt M., Esmat G., George J., Reggiani G. M., Novak K., et al.  
International Liver Congress, ELECTR NETWORK, 23 - 26 June 2021, vol.75
- VII. **CLINICAL PRESENTATION OF LEAN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY**  
YILMAZ Y.  
Digestive Disease Week, United States Of America, 21 May 2021, vol.160, pp.771-772

- VIII. **CLINICAL PRESENTATION AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS: DATA FROM THE GLOBAL LIVER REGISTRY (TM)**  
YILMAZ Y.  
Digestive Disease Week, United States Of America, 21 May 2021, vol.160, pp.821-822
- IX. **A GLOBAL SURVEY OF PHYSICIANS KNOWLEDGE ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)**  
YILMAZ Y.  
Digestive Disease Week, United States Of America, 21 May 2021, vol.160, pp.830
- X. **PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C: DATA FROM THE GLOBAL LIVER REGISTRY (TM)**  
Yu M., El Kassas M., Lam B. P., Esmat G., Fernandez M. C., Ferret M. A. B., Papatheodoridis G., Isakov V. A., Duseja A., YILMAZ Y., et al.  
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72
- XI. **THE IMPACT OF CHRONIC HEPATITIS B ON PATIENT-REPORTED OUTCOMES FROM THE GLOBAL LIVER REGISTRY (TM)**  
YILMAZ Y., Yu M., Lam B. P., Ferret M. A. B., Papatheodoridis G., Chan W. K., Duseja A., Alswat K. A., El Kassas M., Hamid S. S., et al.  
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72
- XII. **SIGNIFICANT KNOWLEDGE GAP ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN REAL-WORLD PRACTICES: A GLOBAL SURVEY OF HEPATOLOGISTS, GASTROENTEROLOGISTS, ENDOCRINOLOGISTS AND PRIMARY CARE PHYSICIANS**  
Younossi Z. M., Takahashi H., Eguchi Y., YILMAZ Y., El Kassas M., Zheng M., Fang J., Wong V. W., Alswat K. A., Chan W. K., et al.  
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72
- XIII. **CLINICAL AND PATIENT-REPORTED OUTCOMES DATA OF NON-ALCOHOLIC FATTY LIVER DISEASE: LONGITUDINAL DATA FROM THE GLOBAL NASH REGISTRY (TM)**  
Younossi Z. M., YILMAZ Y., Yu M., Wong V. W., Castellanos Fernandez M., Isakov V. A., Duseja A., Mendez-Sanchez N., Eguchi Y., George J., et al.  
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72
- XIV. **Comparison of clinical and histological characteristics of biopsyproven non-alcoholic fatty liver patients with and without type 2 diabetes mellitus: 10 years of experience from a single tertiary care center**  
YILMAZ Y.  
APASL 2020 Bali - 29th Annual Conference Asian Pacific Association for the Study of the Liver, Balvi, Latvia, 4 - 08 March 2020, vol.14, pp.1-470
- XV. **THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR)**  
YILMAZ Y.  
Digestive Disease Week, United States Of America, 23 January 2020, vol.158, pp.1269
- XVI. **ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH LIVER STIFFNESS IN BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE: A TRANSIENT ELASTOGRAPHY STUDY**  
YILMAZ Y.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.70, pp.1063-1064
- XVII. **CLINICAL AND PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY**

- YILMAZ Y.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.70, pp.577-578
- XVIII. **DIFFERENCES IN THE CLINICAL PROFILE OF THE MOST COMMON CAUSES OF CHRONIC LIVER DISEASE (CLD) ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY.**  
YILMAZ Y.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.70, pp.463-465
- XIX. **SEVERE IMPAIRMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY**  
YILMAZ Y.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.359
- XX. **CAN ADVANCED FIBROSIS RELIABLY EXCLUDED BY SIMPLE NON-INVASIVE FIBROSIS SCORING SYSTEMS?: PERFORMANCE OF FIB-4 AND NFS IN A BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE SAMPLE**  
YILMAZ Y.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.70, pp.1053-1054
- XXI. **CLINICAL AND PATIENT-REPORTED OUTCOMES DATA FOR PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY**  
YILMAZ Y.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019
- XXII. **ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH LIVER STIFFNESS IN BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE: A TRANSIENT ELASTOGRAPHY STUDY**  
Bilgin B. O., SÜNBÜL M., Kani H. T., Demirtas C. O., KEKLİKKIRAN Ç., YILMAZ Y.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70
- XXIII. **THE UTILITY OF NONINVASIVE SCORES IN ASSESSING THE ADVANCED HEPATIC FIBROSIS IN TYPE 2 DIABETIC PATIENTS WITH BIOPSY PROVEN NONALCOHOLIC FATTY LIVER DISEASE**  
Alkayyali T., Quatranji L., Kaya E., Bakir A., YILMAZ Y.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70
- XXIV. **USEFULNESS OF ENDOSCOPIC ULTRASONOGRAPHY ELASTOGRAPHY (EUS-E) TO MEASURE LIVER STIFFNESS**  
Duman D. G., Alahdab Y., Demirtas C. O., YILMAZ Y., GÜNDÜZ F.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70
- XXV. **Liver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease**  
Sun D., Fun Zhou Y., Kani H. T., Chen Fei Z., Pei Wu Z., Hong Lei M., Wen Yue L., Hao Yang Z., Xiao Dong W., Wei Jie Y., et al.  
EASL 2019, Paris, France, 14 April 2019
- XXVI. **Liver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease**  
Sun D. Q., Ye F., Haluk Tarik K., Zheng C., Zhu P., Ma H., Liu W., Zhang H., Wang X., Yuan W., et al.  
International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Austria, 10 - 14 April 2019, vol.70

- XXVII. **Translating NAFLD AASLD data to local practice**  
YILMAZ Y.  
AASLD TASL Regional Connect Meeting, İstanbul, Turkey, 15 - 16 March 2019
- XXVIII. **Nonalcoholic Fatty Liver Disease(NAFLD) and Alcoholic Fatty Liver Disease(AFLD): The impact of Alcohol Comsumption and Metabolic Syndrome on Mortality**  
Younossi Z., Stepanova M., Ong J., Yilmaz Y., Duseja A., Eguchi Y., Kassas M. E., Fernandez M., George J., Jacobson I., et al.  
THE AASLD LIVER MEETING, South-Carolina, United States Of America, 9 - 13 November 2018
- XXIX. **Noninvazif Fibrozis ve Yağlanma Ölçümü:Fibroscan/CAP**  
YILMAZ Y.  
4. Azerbaijan-Türkiye Ortak Hepatoloji Kursu, Baku, Azerbaijan, 06 October 2018
- XXX. **Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Fatty Liver Disease (AFLD): The Impact of Alcohol Consumption and Metabolic Syndrome on Mortality**  
Younossi Z. M., Stepanova M., Ong J., YILMAZ Y., Duseja A. K., Eguchi Y., El Kassas M., Fernandez M., George J., Jacobson I. M., et al.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Costa Rica, 9 - 13 November 2018, vol.68
- XXXI. **Non-alcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma listed for liver transplantation in United States: data from the Scientific Registry of Transplant Recipients**  
Younossi Z., Stepanova M., Ong J., Jacobson I., Bugianesi E., Duseja A., Eguchi Y., Wong V., Negro F., YILMAZ Y., et al.  
Joint International Congress of ILTS, ELITA and LICAGE, Lisbon, Portugal, 23 - 26 May 2018, vol.102, pp.304-305
- XXXII. **Transient elastography with controlled attenuation parameterin the assessment of hepatic steatosis and significant liver fibrosisin patients with scleroderma**  
Yilmaz Y., Kani H. T., Şahinkaya Y., Mursaloglu H. H., Aziziy M., İnanç G. N., Direskeneli R. H.  
27th Annual Conference of APASL, Dilli, India, 14 - 18 March 2018, vol.12, pp.378
- XXXIII. **Klinik pratikte transiyent elastografi kullanımı**  
YILMAZ Y.  
Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaijan, 21 January 2018
- XXXIV. **Tanıdan tedaviye alkole bağlı olmayan yağlı karaciğer hastalığı**  
YILMAZ Y.  
Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaijan, 21 January 2018
- XXXV. **Karaciğer fibrozisinin değerlendirilmesinde elastografinin rolü**  
YILMAZ Y.  
Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaijan, 21 January 2018
- XXXVI. **Preliminary evidence of an association between mtDNA D-loop polymorphisms and the clinicopathological features of nonalcoholic steatohepatitis**  
Hasturk B., Yilmaz Y., Eren F.  
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 October 2017, vol.66
- XXXVII. **Nonalcoholic steatohepatitis: modulation of histological phenotype by the missense Thr174Met (rs4762) polymorphism of the angiotensinogen (AGT) gene**  
EREN F., Balcilar H., Yilmaz D., Toker T., YILMAZ Y., Hasturk B.  
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 October 2017, vol.66
- XXXVIII. **Mitochondrial DNA control region nucleotide variations in non-alcoholic steatohepatitis**  
Hasturk B., Yilmaz Y., Eren F.  
European Biotechnology Congress, Dubrovnik, Croatia, 25 - 27 May 2017, vol.256
- XXXIX. **Prevalence of Fatty Liver in IBD: ATransient Elastography Study on the Basis of a Controlled AttenuationParameter**  
Kani H. T., Demirtas I., Yilmaz Y.  
The 5th Annual Meeting of Asian Organization for Crohn's Colitis, Seoul, South Korea, 15 - 17 June 2017, pp.235-

- XL. **Prevalence of fatty liver in inflammatory bowel disease : a transient elastography study on the basis of a controlled attenuation parameter.**  
YILMAZ Y., KANI H. T.  
5th Annual Meeting of the Asian Organization for Crohn's and Colitis, Seul, South Korea, 15 - 17 June 2017
- XLI. **NAFLD: Yeni ne var?**  
YILMAZ Y.  
11. Ulusal Hepatoloji Kongresi, Antalya, Turkey, 17 - 21 May 2017
- XLII. **Marmara Üniversitesi Tıp Fakültesi Harvoni Deneyimi**  
YILMAZ Y.  
Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Turkey, 28 - 29 April 2017
- XLIII. **Hepatit C Tedavilerinin İlaç Etkileşimleri**  
YILMAZ Y.  
Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Turkey, 28 - 29 April 2017
- XLIV. **NASH'te yeni ne var?**  
YILMAZ Y.  
14. Ulusal Hepatogastroenteroloji Kongresi, Antalya, Turkey, 5 - 08 April 2017
- XLV. **Yüzyılın Epidemisi Alkol Dışı Karaciğer Yağlanması Hastalığı**  
YILMAZ Y.  
33. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 22 - 27 December 2016
- XLVI. **COMPARISON OF DOPPLER ULTRASOUND AND TRANSIENT ELASTOGRAPHY FOR DIAGNOSIS OF SIGNIFICANT FIBROSIS IN NONALCOHOLIC STEATOHEPATITIS**  
ERGELEN R., YILMAZ Y., ASADOV R., CELİKEL Ç., AKIN H., BUGDAYCI O., ALTUN E., TUNEY D.  
ESGAR, 14 - 16 December 2016
- XLVII. **Obezite ve yağlı karaciğer**  
YILMAZ Y.  
7. Ulusal Obezite Kongresi, İstanbul, Turkey, 8 - 11 December 2016
- XLVIII. **Sülfasalazin kullanımı sonrası gelişen Dress sendromu Olgu sunumu**  
DURĞAY M., AYKUT U. E., ÖZEN ALAHDAB Y., YILMAZ Y., DEMİR O.  
33. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 22 - 27 November 2016
- XLIX. **İrritabl barsak sendromlu hastalarda yüksek laktoz intolerans sıklığı**  
hasanov r., ÖZEN ALAHDAB Y., EREN F., GÜNDÜZ F., YILMAZ Y., AYKUT U. E.  
33.Uluslararası gastroenteroloji haftası, Turkey, 22 - 27 November 2016
- L. **Türk toplumunda alkolik olmayan yağlı karaciğer hastalığının genetik polimorfizm ile ilişkisi çok merkezli kontrollü çalışma**  
UYGUN A., öztürk k., DEMİRCİ H., öztuna a., EREN F., YILMAZ Y., KOZAN S., KURT Ö., KİLCİLER A. G., vatansever s., et al.  
33.Uluslararası gastronetroloji haftası, Antalya, Turkey, 22 - 27 November 2016
- LI. **Two atypical forms of Nonalcoholic fatty liver disease NAFLD without metabolic syndrome and Lean NAFLD**  
YILMAZ Y.  
APASL Single Topic Conference, İstanbul, Turkey, 22 - 24 September 2016
- LII. **Bactericidal permeability increasing protein has no effect on remission of ulcerative colitis**  
EREN F., eroğlu k., Banzragch M., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., YILMAZ Y., ATUĞ Ö., İMERYÜZ N., AKIN H.  
The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japan, 7 - 09 July 2016
- LIII. **MT ND5 gene variants have both protective and risk factor for inflammatory bowel disease**  
Eren F., Safarova C., Gündüz F., Özgen Alahdab Y., Kurt R., Yilmaz Y., Atug Ö., İmeryüz N., Akın H.  
The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japan, 7 - 09 July 2016
- LIV. **Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis**

- ERGELEN R., YILMAZ Y., ASADOV R., ÇELİKEL Ç., AKIN H., BUGDAYCI O., ALTUN E., TUNEY D.  
European Society of Gastrointestinal and Abdominal Radiology, 14 - 17 June 2016
- LV. **Yağlı Karaciğerde Yeni İlaç Tedavileri**  
YILMAZ Y.  
Klinik Gastroenteroloji Toplantısı-5, İstanbul, Turkey, 02 June 2016
- LVI. **Kronik Viral Hepatitlerde Non İnvazif Yöntemle Fibrozis Belirleme Algoritmeleri**  
YILMAZ Y.  
Hepatit B Enfeksiyonu Akademisi, Çanakkale, Turkey, 28 May 2016
- LVII. **Controlled attenuation parameter and liver stiffness measurements by fibroscan for the detection of non alcoholic fatty liver disease in patients with type 2 diabetes results from a pilot study**  
DURĞAY M., DEYNELİ O., YILMAZ Y.  
EASL monothematic conference 2016, Riga, Latvia, 12 - 14 May 2016
- LVIII. **Karaciğer Hasarının Değerlendirilmesi Non İnvazif Testlere Algoritmik Yaklaşım**  
YILMAZ Y.  
XIII. Ulusal Viral Hepatit Kongresi, Antalya, Turkey, 17 - 20 March 2016
- LIX. **Alkol Dışı Yağlı Karaciğer Hastalığında Yeni Ne Var**  
YILMAZ Y.  
TKAD Mezuniyet Sonrası Eğitim Sempozyumu: Karaciğerde Çok Yenilik Var:AASLD 2015'den Süzülenler, İstanbul, Turkey, 13 January 2016
- LX. **Does Helicobacter pylori Infection Influences the Complication rate After Sleeve Gastrectomy From an Endemic Region**  
AKYÜZ Ü., ALTUN H., BURÇİN B., YILMAZ Y., DERYA U.  
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- LXI. **Diyabetik Hastalarda Nonalkolik Yağlı Karaciğer Hastalığının ve Fibrozisin Fibroscan Aracılı CAP ve Karaciğer Sertlik Ölçümü ile Prospektif Taranması Ön Bulgularımız**  
DURĞAY M., DEYNELİ O., YILMAZ Y.  
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- LXII. **NASH Pategenez ve Tedavisinde Yeni Bir Şey Var Mı**  
YILMAZ Y.  
32.Uluslararası Gastroenteroloji Haftası, Antalya, Turkey, 25 - 29 November 2015
- LXIII. **Ülseratif Kolitin ÜK Hastalık Aktivitesi Bakterisidal Permeabilite Arttırıcı Protein BPI Düzeyi ile İlişkilidir**  
EREN F., EROĞLU K., MUNKHTSETSEG B., ALAHDAB Y. Ö., KURT R., YILMAZ Y., İMERYÜZ N., AKIN H.  
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- LXIV. **Karaciğer Fibrozisinde Yeni Non İnvaziv Yöntem ELF Test**  
DURUSOY S. S., ÖZDEMİR F. T., ÖZDOĞAN O. C., RAHMİ A., YILMAZ Y., YEĞİN E. G., AYKUT U. E.  
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- LXV. **Ülseratif kolitin hastalık aktivitesi bakterisidal permeabilite arttıracı protein BPI düzeyi ile ilişkilidir**  
EREN F., eroğlu k., banzragch m., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., YILMAZ Y., ATUĞ Ö., İMERYÜZ N., AKIN H.  
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- LXVI. **NAFLD in absence of Metabolic Syndrome**  
YILMAZ Y.  
FRONTIERS IN HEPATOLOGY Non-alcoholic Fatty Liver Disease & the Metabolic Syndrome – Key questions on disease consequences and treatment –, Londrina, Brazil, 24 November 2015
- LXVII. **Latent tüberküloz tanısında interferon gamma salınım testi ile tüberkülin deri testinin karşılaştırılması**  
ÖZEN ALAHDAB Y., Kedrah A. E., GÜNDÜZ F., YÖNAL O., YILMAZ Y., ALAHDAB H., HAMZAĞLU H.  
BUHASDER 6.Tepcik Enfeksiyon Günleri Sempozyumu, Muğla, Turkey, 4 - 08 November 2015
- LXVIII. **Nonalkolik Yağlı Karaciğerli Hastalarda İleri Evre Fibrozisin Saptanmasında Noninvazif Yeni Bir Yöntem Olan Fibrometer VCTE nin Tanısal Performansı**

- DİNÇSES E., YILMAZ Y.  
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015, vol.26, pp.21
- LXIX. **Aktif Kahverengi Yağ Dokusu Varlığı Yağlı Karaciğer Hastalığı Gelişimini Önlüyor Olabilir**  
Salih Ö., Tunç Ö., YILMAZ Y., TUROĞLU H. T., İMERYÜZ N.  
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015, vol.26, pp.43-44
- LXX. **Non alcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with non alcoholic fatty liver disease**  
SÜNBÜL M., KIVRAK T., DURMUŞ E., AKIN H., AYDIN Y., ERGELEN R., YILMAZ Y., AĞIRBAŞLI M. A.  
31. TURKISH CARDIOLOGY CONGRESS WITH INTERNATIONAL PARTICIPATION, 22 - 25 October 2015
- LXXI. **Can FibroMeter VCTE (TM) be useful for detecting hepatic fibrosis in patients with non-alcoholic fatty liver disease?**  
Dincses E., YILMAZ Y.  
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62
- LXXII. **Can FibroMeter VCTE be useful for detecting hepatic fibrosis in patients with non alcoholic fatty liver disease**  
DİNÇSES E., YILMAZ Y.  
The AASLD Liver Meeting 2015, San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62, pp.1270
- LXXIII. **Yeni Antikoagulanlar İşlem öncesi ve sonrası yaklaşım**  
YILMAZ Y.  
3.Gastrointestinal Endoskopi Günleri, İstanbul, Turkey, 8 - 09 May 2015
- LXXIV. **Characterization of Lean Patients With Nonalcoholic Fatty Liver Disease Potential Role of High Hemoglobin Levels**  
AKYÜZ Ü., YEŞİL A., YILMAZ Y.  
46th Annual Digestive Disease Week (DDW), Washington, Kiribati, 16 - 19 May 2015, vol.148, pp.1058
- LXXV. **Noninvasive tests in the diagnosis of Non Alcoholic Fatty Liver Disease**  
YILMAZ Y.  
The 24th Conference of the Asian Pacific Association for the Study of Liver (APASL), İstanbul, Turkey, 12 - 15 March 2015
- LXXVI. **Yağlı Karaciğer Non alkolik Steatohepatit ve Alkolik Steatohepatit**  
YILMAZ Y.  
Uludağ İç Hastalıkları Kış Kongresi, Bursa, Turkey, 08 March 2015
- LXXVII. **Hepatoselüler Karsinoma Karsinogenezde endokrin metabolik mekanizmalar**  
YILMAZ Y.  
13. Hepatoloji Sempozyumu, Ankara, Turkey, 17 January 2015
- LXXVIII. **Barsak karaciğeri nasıl etkiler**  
YILMAZ Y.  
31. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 24 - 28 November 2014
- LXXIX. **Otoimmün hepatit ilaç hepatotoksitesi yağlı karaciğer ve hepatitte yaklaşım ilaç seçimi ve izlem**  
YILMAZ Y.  
A'dan Z'ye Psöriazis Toplantısı, İstanbul, Turkey, 08 November 2014
- LXXX. **Klinik Araştırma Planlaması**  
YILMAZ Y.  
11. Ulusal HEBİPA Kongresi, Cyprus (Kktc), 24 - 28 September 2014
- LXXXI. **Alkol Dışı Yağlı Karaciğer Hastalığı**  
YILMAZ Y.  
1. TÜRKİYE-AZERBAYCAN ORTAK HEPATOLOJİ KURSU, İstanbul, Turkey, 18 - 19 September 2014
- LXXXII. **Biodegradable Stentler**  
YILMAZ Y.  
Türk Gastroenteroloji Derneği İstanbul Şubesi Mezuniyet Sonrası Eğitim Toplantısı, İstanbul, Turkey, 25 June 2014
- LXXXIII. **Fibrokistik Karaciğer Hastalıkları**

YILMAZ Y.

Türk Karaciğer Araştırmaları Derneği Mezuniyet Sonrası Eğitim Toplantısı, İstanbul, Turkey, 13 June 2014

LXXXIV. **KC biyopsi Fibroscan uygulamaları**

AYGÜN C., YILMAZ Y.

5. Hepatoloji Okulu, Kocaeli, Turkey, 30 May - 01 June 2014

LXXXV. **Karaciğer Transplantasyonlu Hastalarda Metabolik Komplikasyonlar ve Sorunların Yönetimi**

YILMAZ Y.

Organ Nakilleri Bilinçlendirme ve Geliştirme Derneği Karaciğer Nakli Mezuniyet Sonrası Eğitim Kursu 1, İstanbul, Turkey, 24 May 2014

LXXXVI. **Alkol Dışı Yağlı Karaciğer Hastalıkları**

YILMAZ Y.

İSTAHED Kongresi Viral Hepatitler ve Diğer Hepatobilier hastalıklarda Klinik Yaklaşım Kursu, Antalya, Turkey, 10 May 2014

LXXXVII. **Nonalkolik yağlı karaciğer Nonalkolik steatohepatit**

YILMAZ Y.

Türk Karaciğer Vakfı Mezuniyet Sonrası Eğitim Toplantıları, İstanbul, Turkey, 29 March 2014

LXXXVIII. **Erişkinde Yağlı Karaciğer Hastalığı ve Yönetimi Yenilik var mı**

YILMAZ Y.

Karaciğer Hastalıkları ve Transplantasyonu Güncellemeye Toplantısı, İstanbul, Turkey, 01 March 2014

LXXXIX. **Are patients with biopsy proven non alcoholic fatty liver disease at increased risk of asthma Results from a Turkish cross sectional study**

TAŞLI B., YILMAZ Y.

The Asian Pacific Society of Respirology 19th Congress, Balvi, Latvia, 13 - 16 November 2014, vol.19, pp.173-203

XC. **Fibroscan aracılı CAP kronik karaciğer hastalıklarında yağlanması şiddetini hastalık etyolojisinden ve fibrozisten bağımsız olarak doğru tahmin eder**

YILMAZ Y., YEŞİL A., GERİN F., ERGELEN R., AKIN H., ÇELİKEL Ç., İMERYÜZ N.

30. Ulusal Gastroenteroloji Haftası, Turkey, 11 - 15 October 2013

XCI. **CAP yöntemli Fibroscan ile karaciğer yağlanmasıın kantitatif değerlendirilmesi Karaciğer biyopsisi ile karşılaştırmalı prospektif çalışma**

YILMAZ Y., YESİL A., GERİN F., ERGELEN R., AKIN H., ÇELİKEL Ç., İMERYÜZ N.

30. Ulusal Gastroenteroloji Haftası, Turkey, 11 - 15 October 2013

XCII. **Evaluation of gallbladder kinetics in patients with nonalcoholic fatty liver disease**

Colak Y., Bozbey G., Senates E., Doganay L., Coskunpinar E., Ozturk O., Mesci B., Kuru I., Tasan G., YILMAZ Y., et al. 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58

XCIII. **NAFLD da Metformin Hiç Vermeyelim mi**

YILMAZ Y.

10.Uluslararası Hepato Gastroenteroloji Kongresi, Magosa, Cyprus (Kktc), 25 - 29 September 2013

XCIV. **Mikrobiyota ve Nonalkolik Yağlı Karaciğer Hastalığı**

YILMAZ Y.

30. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 11 - 15 September 2013

XCV. **HYPOTHYROIDISM IS NOT ASSOCIATED WITH SPECIFIC HISTOLOGICAL FEATURES OR SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE**

Yilmaz Y., Ayyildiz T., Colak Y., Senates E., Arabul M., Unsal B., Tuncer I., Dolar E.

International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, vol.58

XCVI. **GALLSTONE DISEASE IS NOT ASSOCIATED WITH LIVER FIBROSIS AND NONALCOHOLIC STEATOHEPATITIS IN NONALCOHOLIC FATTY LIVER DISEASE**

Yilmaz Y., Ayyildiz T., Akin H., Colak Y., Ozturk O., Senates E., Tuncer I., Dolar E.

International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, vol.58

- XCVII. A BIOMARKER PANEL WITH HIGH SENSITIVITY AND SPECIFICITY FOR NONALCOHOLIC STEATOHEPATITIS IDENTIFIED BY SUPPORT VECTOR MACHINE**  
Yilmaz Y., Eren F.  
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, vol.58
- XCVIII. HEPATIC EXPRESSION AND SERUM LEVELS OF SYNDÉCAN 1 (CD138) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE**  
Yilmaz Y., Colak Y., Senates E., Celikel Ç., Imeryuz N.  
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, vol.58
- XCIX. Metabolik Sendrom ve NAYK PAtogenezde Yenilikler**  
YILMAZ Y.  
11. Hepatoloji Sempozyumu, Ankara, Turkey, 18 - 19 January 2013
- C. NAFLD patogenezinde yeni ne var Steatoz koruyucu bir mekanizma mıdır**  
YILMAZ Y.  
29. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 20 - 25 November 2012
- CI. NASH Tedavisinde Yenilikler**  
YILMAZ Y.  
9. Ulusal HepatoGastroenteroloji Kongresi, Magosa, Cyprus (Kktc), 26 - 30 September 2012
- CII. Non viral Hepatoselüler Kanser Etyolojisi NAFLD Alkol ve Diğer Faktörler**  
YILMAZ Y.  
4. Hepatoloji Okulu, Muğla, Turkey, 25 - 26 May 2012
- CIII. Patogenezde VAT mı önemli SAT mı Günlük yaşamda fruktoz sanıldığı kadar suçlu mu**  
YILMAZ Y.  
NAFLD Sempozyumu, Ankara, Turkey, 24 March 2012
- CIV. Association of MDRI Gene and Helicobacter pylori in the Development of Gastric Cancer and Gastritis**  
Eren F., Imeryuz N., Bas E., Ozkan N., Ozdemir F. T., Yilmaz Y., Celikel Ç., Avsar E., Tozun N. A., Ozer A.  
Conference on Digestive Disease Week 2011, Illinois, United States Of America, 7 - 10 May 2011, vol.140
- CV. CIRCULATING LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF) AND ITS SOLUBLE RECEPTOR SVEGFR-1 IN PATIENTS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE**  
Yilmaz Y., Alahdab Y. O., Kurt R., Yonal O., Eren F., Kalayci C., Avsar E.  
46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Germany, 30 March - 03 April 2011, vol.54
- CVI. SERUM LEVELS OF OSTEOPROTEGERIN IN THE SPECTRUM OF NONALCOHOLIC FATTY LIVER DISEASE**  
Yilmaz Y., Yonal O., Kurt R., Eren F., Imeryuz N., Kalayci C., Avsar E.  
46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Germany, 30 March - 03 April 2011, vol.54
- CVII. PLASMA LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPOLYMER PRODUCTS (SRAGE) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE**  
Yilmaz Y., Ulukaya E., Gul O. O., Arabul M., Gul C. B., Atug O., Oral A. Y., Dolar E.  
44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Copenhagen, Denmark, 22 - 26 April 2009, vol.50

## Activities in Scientific Journals

Hepatology Forum, Assistant Editor/Section Editor, 2020 - Continues

Alimentary Pharmacology & Therapeutics, Committee Member, 2020 - Continues

## **Memberships / Tasks in Scientific Organizations**

European Association for the Study of the Liver, Member, 2011 - Continues

## **Scientific Refereeing**

International Journal of Medical Arts, Journal Indexed in ESCI, September 2020  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, September 2020  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, September 2020  
GASTROENTEROLOGY RESEARCH AND PRACTICE, SCI Journal, September 2020  
BIOMED RESEARCH INTERNATIONAL, Journal Indexed in SCI-E, August 2020  
ARCHIVES OF MEDICAL RESEARCH, SCI Journal, August 2020  
JOURNAL OF DIABETES AND ITS COMPLICATIONS, Journal Indexed in SCI-E, August 2020  
İSTANBUL TIP FAKÜLTESİ DERGİSİ, National Scientific Refreed Journal, August 2020  
DIABETES RESEARCH AND CLINICAL PRACTICE, Journal Indexed in SCI-E, July 2020  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, July 2020  
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, National Scientific Refreed Journal, July 2020  
Clinical and Molecular Hepatology, Journal Indexed in ESCI, July 2020  
HEPATOBILIARY SURGERY AND NUTRITION, SCI Journal, July 2020  
JGH Open, Journal Indexed in ESCI, July 2020  
BMC GASTROENTEROLOGY, SCI Journal, June 2020  
CHINESE MEDICAL JOURNAL, Journal Indexed in SCI-E, June 2020  
CANADIAN JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, May 2020  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, May 2020  
Exploration of Medicine, Other Indexed Journal, May 2020  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, March 2020  
LIVER INTERNATIONAL, SCI Journal, March 2020  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, July 2019  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, June 2019  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, May 2019  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, March 2019  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, February 2019  
LIVER INTERNATIONAL, SCI Journal, November 2016  
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, SCI Journal, November 2016  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, October 2016  
LIVER INTERNATIONAL, SCI Journal, September 2015  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, July 2015  
JOURNAL OF HEPATOLOGY, SCI Journal, June 2015  
JOURNAL OF HEPATOLOGY, SCI Journal, June 2015  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, May 2015  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, April 2015  
LIVER INTERNATIONAL, SCI Journal, August 2014  
LIVER INTERNATIONAL, SCI Journal, June 2014  
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, SCI Journal, April 2013

## **Scientific Research / Working Group Memberships**

Yağlı Karaciğer Çalışma Grubu, Türk Karaciğer Araştırmaları Derneği, Turkey, <http://www.tasl.org.tr/>, 2020 - Continues  
The Global Nash Council, Center for Outcomes Research in Liver Diseases, Turkey, <https://www.corlrd.org/global-nash->

council/, 2018 - Continues

The Global Liver Registry, Center For Outcomes Research in Liver Diseases, Turkey, <https://www.corld.org/global-liver-registry/>, 2018 - Continues

## Metrics

Publication: 362

Citation (WoS): 6082

Citation (Scopus): 6328

H-Index (WoS): 36

H-Index (Scopus): 37

## Congress and Symposium Activities

AASLD Annual Meeting, Working Group, Massachusetts, United States Of America, 2019

World Congress of Gastroenterology, Invited Speaker, İstanbul, Turkey, 2019

The NAFLD Summit 2019, Working Group, Sevilla, Spain, 2019

International Conference on Fatty Liver, Working Group, Berlin, Germany, 2019

Working Group, California, United States Of America, 2019

The EASL International Liver Congress, Working Group, Vienna, Austria, 2019

17th Euroasian Congress of Hepato-Gastroenterology and Surgery, Invited Speaker, Split, Croatia, 2019

AASLD TASL Regional Connect Meeting, Invited Speaker, İstanbul, Turkey, 2019

Asian Pacific Association for the Study of the Liver Annual Meeting, Working Group, Manila, Philippines, 2019

Global NASH Council Meeting, Invited Speaker, California, United States Of America, 2018

APASL Single Topic Conference, Invited Speaker, İstanbul, Turkey, 2016

FRONTIERS IN HEPATOLOGY Non-alcoholic Fatty Liver Disease & the Metabolic Syndrome – Key questions on disease consequences and treatment , Invited Speaker, London, United Kingdom, 2015

## Awards

Yılmaz Y., 'Dünyanın En Etkili Bilim İnsanları Listesi'nde Türkiye'den Gastroenteroloji alanındaki tek kişi, Plos Biology, July 2020

Eren F., Yılmaz Y., Hayat Bulan Fikirler Proje Destek Ödülü, Gilead, November 2019

Yılmaz Y., Eren F., Hayat Bulan Fikirler Proje Destek Ödülü, Gilead, November 2018

Yılmaz Y., Tıp Bilimine Yön Veren 100 Türk, Turkishtime, September 2018

Yılmaz Y., Hayat Bulan Fikirler Proje Destek Ödülü, Gilead, November 2017

Yılmaz Y., En Yüksek Atif Ödülü, Marmara Üniversitesi, January 2013

Yılmaz Y., Bayındır Tıp Teşvik Ödülü, Bayındır Holding, January 2012

Yılmaz Y., En Fazla Bilimsel Yayın Puanına Sahip Hekim Ödülü, İstanbul İl Sağlık Müdürlüğü, January 2011

Yılmaz Y., Eczacıbaşı Bilim Teşvik Ödülü, Eczacıbaşı Holding, January 2011

Yılmaz Y., Sağlık Bilimleri Alanında En Yüksek Yayın Performans Ödülü, Marmara Üniversitesi, January 2011

Yılmaz Y., Üstün Başarı Ödülü, Marmara Üniversitesi Tıp Fakültesi, January 2010

Yılmaz Y., Yayın Özel Ödülü, Uludağ Üniversitesi, January 2009

Yılmaz Y., Zafer Paykoç Ödülü, Türkiye Hepatoloji Vakfı, January 2007

## Non Academic Experience

Şanlıurfa Siverek Devlet Hastanesi